



2030 AUSTRALIAN STRATEGY FOR

# foot health & disease in diabetes

Improving the foot health of  
people living with diabetes

# Authors

Members of the Diabetes Feet Australia National Strategy sub-committee

Byron M Perrin<sup>1,2</sup>, Emma J Hamilton<sup>2-4</sup>, Vivienne Chuter<sup>2,5</sup>, Joel WJ Lasschuit<sup>2,6-9</sup>, Laurens Manning<sup>2,4,10</sup>, Pam Chen<sup>2,11,12</sup>, Jane Cheney<sup>13</sup>, James Charles<sup>14</sup>, Jonathan Golledge<sup>2,15,16</sup>, Jaap J van Netten<sup>17-19</sup>, Peter A Lazzarini<sup>19,20</sup>

## Affiliations

1. La Trobe Rural Health School, La Trobe University, Bendigo, VIC, Australia
2. Diabetes Feet Australia, Sydney, NSW, Australia
3. Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Murdoch, WA, Australia
4. Medical School, University of Western Australia, Perth, WA, Australia
5. School of Health Sciences, Western Sydney University, Campbelltown, NSW, Australia
6. Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, NSW, Australia
7. Clinical Diabetes, Appetite and Metabolism Lab, Garvan Institute of Medical Research, NSW, Australia
8. St Vincent's Clinical Campus, School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia
9. National Association of Diabetes Centres, Australian Diabetes Society, NSW, Australia
10. Department of Infectious Diseases, Fiona Stanley Hospital, Perth, WA, Australia
11. Podiatry Department, Fiona Stanley Hospital, Murdoch, WA, Australia
12. School of Allied Health, Curtin University, Curtin, WA, Australia
13. Diabetes Victoria, Melbourne, VIC, Australia
14. First Peoples Health Unit, Griffith University, Gold Coast, QLD, Australia
15. Queensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, QLD, Australia
16. Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, QLD, Australia
17. Department of Rehabilitation Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands
18. Amsterdam Movement Sciences, Program Rehabilitation, Amsterdam, the Netherlands
19. School of Public Health and Social Work, Queensland University of Technology, Brisbane, QLD, Australia
20. Allied Health Research Collaborative, The Prince Charles Hospital, Brisbane, QLD, Australia

\*Correspondence to: [b.perrin@latrobe.edu.au](mailto:b.perrin@latrobe.edu.au)

Suggested citation

Perrin BM, Hamilton EJ, Chuter V, Lasschuit JWJ, Manning L, Chen P, Cheney J, Charles J, Golledge J, van Netten JJ, Lazzarini PA. Australian strategy for foot health and disease in diabetes 2030. Sydney, Australia: Diabetes Feet Australia, Australian Diabetes Society; 2025

## Acknowledgments

The members of the Diabetes Feet Australia (DFA) National Strategy sub-committee acknowledge and thank the following DFA Steering Committee members for their contribution to the planning, preparation, and review of this document: Professor Stephen Twigg, Associate Professor Sof Andrikopoulos, Natalie Wischer OAM, Professor Rob Fitridge, Professor Anthony Russell, Hayley Ryan, James Gerrard, Nyasha Purcell, Operations Manager of DFA, provided invaluable administrative support for the subcommittee and prepared the final document.



The authors would like to acknowledge and pay their respects to the Traditional Custodians of the lands on which they live and work. This work includes the nomenclature; First Nations Peoples, First Nations Communities, First Nations people, Aboriginal and Torres Strait Islander Peoples, Aboriginal and Torres Strait Islander people and Indigenous. Neither singularly, nor collectively do they adequately represent the immense diversity of language groups and cultural values across this continent's Traditional Custodians and Sovereign Owners. Non-Indigenous people is the language used to represent and be inclusive of Australians who are not First Nations people.


Diabetes Feet Australia (DFA) recognises that language is powerful.<sup>1,2</sup> Throughout this document and its broader work DFA attempts to decolonise language and prioritise strength-based approaches that reflect the complex multifactorial nature of diabetes and diabetes-related foot disease and acknowledge and value peoples' lived experience of disease.

# PLAIN LANGUAGE SUMMARY

Diabetes can cause serious foot problems, which can lead to hospital visits, amputations (losing a part of the foot or leg), and high medical costs. These foot problems include things like not being able to feel the feet, poor blood flow, sores, and infections.

## KEY STATISTICS

### ● EACH YEAR IN AUSTRALIA



## NEW PLAN

The **Australian Strategy for Foot Health and Disease in Diabetes 2030**: improving the foot health of people living with diabetes is a new plan to help people with diabetes take better care of their feet and prevent serious foot problems. This plan targets how to improve the foot health of all people with diabetes in three main ways.

**A**

Better access to care for everyone

**B**

Make sure care is good quality

**C**

More research and development

# A

## Better access to care for everyone

1

### Annual foot checkups

Make sure all people with diabetes get their feet checked yearly by a health professional to see how likely they are to get foot problems and catch them early.

2

### Care to prevent foot problems

When people are found to be more likely to get foot problems, they should get regular foot care, wear the right shoes, and learn how to keep their feet healthy.

3

### Special care teams for foot sores

When someone has a sore on their foot, they should get care from a special team of foot care experts to prevent it from getting worse.

4

### Good foot care service standards

Make sure the rules for foot care services are based on the latest research and services follow these rules to do a good job for patients.

5

### Collect foot care information

Collect information about foot care services to make sure they keep improving and give better results for patients.

6

### Good foot care guidelines

Regularly update the guidelines that tell health professionals how to best treat foot problems, based on the latest research.

# B

## Make sure care is good quality

7

### More money for research

Lobby for more money for research (an extra \$30 million per year) to learn more about how to help people with foot problems get better faster.

8

### Plan for research

Make sure the money spent on more research is spent in the best ways to help different communities with foot problems.

9

### Create a research network

Set up a national group of scientists and researchers to work together, learn from each other, and teach new researchers to help foot care get better faster.

# C

## More research & development



If we follow this plan, the foot health of those living with diabetes should improve, and we can greatly reduce hospital visits, amputations, and medical costs in Australia.

# Table of contents

Acknowledgments	2
Plain Language Summary	3
Executive Summary	6
Section 1 Background	8
Section 2 The latest impacts of diabetes-related foot disease	12
Section 3 Australian National Strategy for Foot Health and Disease 2030	16
Methodology	16
Principles	17
Enablers	18
A Access to Affordable, Culturally Responsive and Effective Care	20
<b>GOAL 1</b> All people living with diabetes need access to culturally responsive evidence-based annual screening to determine their risk of diabetes-related foot ulcers and inform their risk-based footcare	20
<b>GOAL 2</b> All people at risk of diabetes-related foot ulcers need access to recommended culturally responsive evidence-based preventative footcare from trained health professionals	22
<b>GOAL 3</b> All people with active diabetes-related foot disease need access to clinically safe and culturally responsive evidence-based healthcare from interdisciplinary High Risk Foot Services	25
B Provision of Safe Quality Care	29
<b>GOAL 4</b> All people living with diabetes-related foot disease should have access to interdisciplinary High Risk Foot Services that meet evidence-based standards	29
<b>GOAL 5</b> All health service regions should report their diabetes-related foot disease outcomes annually and contribute standardised data to a registry that enables benchmarking and collaboration	32
<b>GOAL 6</b> Australian national diabetes-related foot disease guidelines should continually reflect the most up-to-date evidence to guide best practice standards for healthcare provision across Australia	35
C Research and Development	37
<b>GOAL 7</b> Research investment for diabetes-related foot disease should be proportional to its impact on Australians	37
<b>GOAL 8</b> An Australian foot health and disease in diabetes research framework responsive to local and national priorities should be developed	39
<b>GOAL 9</b> An Australian foot health and disease in diabetes research network should be established	41
Abbreviations	44
Appendices	45
<b>Appendix 1</b> Health professional disciplines who may be involved in the care of a person with DFD	44
<b>Appendix 2</b> Tables 1-3 with footnotes	45
References	49



## EXECUTIVE SUMMARY

In 2017, Diabetes Feet Australia (DFA) published the Australian diabetes-related foot disease strategy 2018–2022: The first step towards ending avoidable amputations within a generation. This pioneering strategy aimed to guide the nation towards reducing the substantial impacts of diabetes-related foot disease (DFD) on Australians and Australia. To deliver such nation-wide reductions in DFD impacts, the strategy proposed 32 areas for action that if addressed would likely achieve 9 key goals and in turn improve care across three overarching priorities: improve access to care, safe quality care, and research and development.


Since publication, initiatives addressing some areas for action have been enacted, some key goals achieved and some impacts of DFD reduced on Australians and Australia. However, progress against these key goals and priorities has been inconsistent. For instance, there has been significant progress towards establishing safe quality care for people with DFD via the establishment and implementation of extensive national clinical guidelines and national clinical service standards. Yet, there has been limited progress made towards obtaining the increased resources required for appropriate access to preventative care or much needed research and development. In turn, there has been inconsistent progress towards reducing the impacts of DFD in Australia. There has been reductions in diabetes-related major lower limb amputation rates in Australia, which is a significant national achievement. Yet, there have been increases in DFD-related hospitalisation, minor amputation and disability rates in Australia, which is a significant national concern.

This new **Australian Strategy for Foot Health and Disease in Diabetes 2030: improving the foot health of people living with diabetes** has been developed by an expert national strategy sub-committee of DFA. The sub-committee reviewed all areas for action, key goals, priorities, and impacts since 2017, determined key principles and enablers to underpin the new strategy, and has renewed all areas for action, key goals and priorities to be achieved by 2030 (Figure 1). This new updated national strategy not only builds upon the recent successes of the first strategy in improving some key goals, priorities and impacts, but also identifies new areas for actions and some that still require urgent attention.

Figure 1 displays the principles, enablers, key goals and overarching priorities of the new Australian Strategy for Foot Health and Disease in Diabetes 2030: improving the foot health of people living with diabetes. DFA has evaluated that by fully implementing this new national strategy, that this will not only substantially improve the foot health of the over 1.5 million Australians with diabetes, but should also help prevent an estimated 20,250 hospitalisations, 2,840 amputations and \$940 million in healthcare costs per year for Australia.

“

DFA has evaluated that by fully implementing this new national strategy, that this will not only substantially improve the foot health of the over 1.5 million Australians with diabetes, but should also **help prevent an estimated 20,250 hospitalisations, 2,840 amputations and \$940 million in healthcare costs per year for Australia.**



**Figure 1** Principles, enablers, key goals and overarching priorities of the Australian Strategy for Foot Health and Disease in Diabetes 2030: improving the foot health of people living with diabetes

**Diabetes Feet Australia (DFA)** was established in 2015, is a division of the Australian Diabetes Society (ADS) and is the peak national clinical and research body for foot health and disease in diabetes. Supported by an Operations Manager, DFA is led by a volunteer national steering committee comprised of a range of clinical and research expert members from disciplines including endocrinology, vascular surgery, infectious diseases, nursing, and podiatry. Members also bring a wealth of experience as representatives on various international, national, and state DFD groups, including the International Working Group on the Diabetic Foot and DFoot International.

DFA has four overarching objectives:

- Optimise national evidence-based and culturally responsive clinical practice for foot health in diabetes
- Stimulate national research in foot health in diabetes
- Reduce national diabetes-related lower limb amputation rates
- Empower Australia to become a leading nation in foot health in diabetes management

A foundational publication produced by DFA was the Australian DFD Strategy 2018–2022: The first step towards ending avoidable amputations within a generation strategy document.<sup>7,8</sup> To reduce the substantial national impacts of DFD on Australian, the 2018–2022 strategy clearly outlined 32 areas for action that if addressed would likely achieve 9 key goals and in turn improve care across 3 overarching priority areas: improve access to care, safe quality care, and research and development.

Since then, DFA has led many key initiatives addressing these areas for action to help reduce the impacts of DFD on Australians and Australia.

## KEY INITIATIVES LED BY DFA

Publication of Australian evidence-based guidelines for the care of people at risk or with DFD<sup>3</sup>

Publication of National top research priorities for prevention and management of DFD<sup>4</sup>

Publication of Australian guidelines on footwear for people with diabetes<sup>5</sup>

Publication of Australian diabetic foot ulcer minimum data dictionary to standardise data collection<sup>6</sup>

Hosting the largest biennial national DFD conferences in the Southern Hemisphere

Hosting continual professional development activities for DFD stakeholders

Hosting the inaugural National Diabetes Feet Day held in November 2024

Providing ongoing support for other national public awareness campaigns

Providing ongoing national advocacy for DFD via submissions to government inquiries

Providing ongoing national promotion and support for research projects

This new **Australian Strategy for Foot Health and Disease in Diabetes 2030: improving the foot health of people living with diabetes** has been developed by DFA to ensure Australia has a strong contemporary national strategy that reflects international best practice, considers latest impacts of DFD in Australia and helps position Australian communities to continually improve the foot health of people living with diabetes and reduce the impacts of DFD across the nation.





# The Australian community involved in diabetes foot health

The Australian community involved in diabetes foot health is wide and diverse. DFA aims to work in collaboration with all key stakeholders in this community, including people with lived experience, their families and carers, health professionals, researchers, and industry.

## People with lived experience

At the forefront of this community are people living with diabetes and their families and carers. Around one third of people living with diabetes have DFD. DFD is defined as disease of the foot in a person with diabetes that includes one or more of the following conditions: peripheral neuropathy, peripheral artery disease, infection, ulcer(s), Charcot neuro-osteoarthropathy, gangrene, or amputation.<sup>9</sup> Unfortunately, DFD is the leading cause of hospitalisations, amputations, disability burdens and healthcare costs in people living with diabetes in Australia.<sup>10,11</sup>

DFA is committed to working in partnership with and for people living with diabetes and DFD to help improve their foot health outcomes and in turn reduce the large health impacts caused by DFD on the nation. People living with diabetes have different personal strengths and coping strategies, and fostering a positive and collaborative relationship between people with lived experience and healthcare professionals empowers individuals to manage their diabetes and their foot health. This is particularly important if people develop DFD, as it can be especially challenging for a person to maintain their foot health when they may also be experiencing other diabetes complications.

DFA has a healthy track record of working with people living with diabetes across geographically diverse regions and with Aboriginal and Torres Strait Islander people as evidenced in the development of the recent Australian evidence-based clinical guidelines and the National top research priorities for people with or at risk of DFD.<sup>3,4</sup> Furthermore, DFA has committed to establish a national consumer advisory committee to ensure people with lived experience of DFD is at the core of everything DFA does and considers Diabetes Australia the key partner in advocating for people affected by diabetes.

## Health Professionals

DFA is a division of the Australian Diabetes Society (ADS). The ADS is the peak national medical and scientific body for diabetes in Australia and is a member-based organisation consisting of endocrinologists, scientists, researchers, diabetes educators, allied health professionals and primary care practitioners. The ADS has four key strategic pillars: Advocacy, Clinical Guidelines/Standards, Education, and Research; and works in close collaboration with its affiliated partners, including Diabetes Australia and the Australian Diabetes Educators Association. It is committed to improving diabetes treatment and care, increase research funding, advocacy for health policies around diabetes and its prevention, and to support the person with diabetes to live well.<sup>12</sup>

Whilst DFA is the DFD division of ADS and has led the development of multiple national health professional projects in the field, it does this as part of a large multi-disciplinary community of peak national health professional organisations, such as the Australian and New Zealand Society for Vascular Surgery, Australian Orthotic Prosthetic Association, Australian Podiatry Association, Advanced Practising Podiatrists – High Risk Foot Group (APP-HRF), National Association of Diabetes Centres (NADC), Podiatric Association of Australia, South Australian Health and Medical Research Institute's (SAHMRI) Aboriginal and Torres Strait Islander Foot Complications Program and Wounds Australia; all of these organisations endorsed the Australian evidence-based DFD guidelines.

Other national health professional-led projects include the NADC national interdisciplinary High Risk Foot Service (iHRFS) accreditation program, Australian Diabetes Foot Registry, FootForward project, SAHMRI's Aboriginal and Torres Strait Islander Foot Complications Program and Wounds Australia's recent success in advocating for the new federally funded Chronic Wound Consumables Scheme.

## Researchers

The Australian DFD research community is growing and becoming increasingly skilled, collaborative and productive, with a significant increase in research productivity shown over the past 10 years.<sup>13</sup> There has been some pockets of success in obtaining significant funding for DFD research, but much of this recent research productivity has been achieved in the context of disproportionately low research funding for the field. However, with appropriate research funding, Australia's research community is appropriately skilled, collaborative and ready to undertake large-scale research projects that align with wider DFD community priorities and make substantial impacts on improving the foot health of people living with diabetes and reducing the burdens of DFD on the nation.

## Industry

Industry partners are vitally important to support innovation in health care, research translation, engagement, and education. Industry partners have been strong supporters of the DFA national conferences and other DFD community events, sponsor educational events and work with health professionals and researchers to enable best practice, culturally responsive and accessible care.

# Progress towards goals of the last Australian DFD Strategy

In preparation for developing this new Australian strategy, the DFA steering committee initially met to rate by consensus the nation's progress in achieving the 9 key goals outlined in the first Australian DFD Strategy 2018–2022: The first step towards ending avoidable amputations within a generation document. This culminated in the DFA committee releasing a national report card on the first strategy by rating the achievement of the 9 key goals in the first strategy, identifying 2 goals rated as completed, 5 partially completed and 2 not completed (Figure 2).

Those key goals rated as completed included a new national accreditation system for iHRFS (Goal 4) and a new suite of Australian national evidence-based DFD guidelines (Goal 6). Those partially completed included new national screening pathways (Goal 1), funding new state-wide iHRFS based on the needs of people with DFD by some Australian State Governments (Goal 3), a new Australian DFD registry (Goal 5), identification of Australian top research priorities (Goal 7) and evidence of multiple national funding applications for clinical trials and other studies (Goal 8). Those not completed included no new government funding achieved for preventative services (Goal 2) or to make national DFD research funding proportionate to the national burden that DFD causes (Goal 9).

## NATIONAL REPORT CARD



**Figure 2** Australia's national report card toward achieving the 9 key goals of the Australian DFD strategy 2018–2022: The first step towards ending avoidable amputations within a generation

An important area not included in the inaugural strategy or considered in the report card was cultural responsiveness. Thus, it is unclear the level of cultural responsiveness of the initiatives implemented to address the areas for action. For its part, DFA is committed to continually learning and unlearning to develop and support culturally responsive evidence-based healthcare for DFD, and as such recognises and acknowledges the omission of cultural responsiveness in the inaugural strategy and national report card. However, cultural responsiveness was at the forefront of the DFA development of the 2021 Australian evidence-based DFD Guidelines, which privileges First Nations Voices, Knowledges and Cultures. DFA also recognises the amendment to embed cultural safety in the Health Practitioner Regulation National Law Act under the Australian Health Practitioner Registration Agency.<sup>14,15</sup> As part of these changes a new objective is to build the capacity of the Australian health workforce to provide culturally safe and respectful health services to Aboriginal and Torres Strait Islander people that are guided by principles of responsiveness and contributing to the elimination of racism in the provision of health services.<sup>14,15</sup> Furthermore, DFA acknowledges that First Nations Communities are diverse and implementation of recommendations in this strategy will require both flexibility and local community consultation and engagement.

The DFA national report card shows that there has been significant, but inconsistent, progress when assessed against the original 9 key goals. What must also be considered in preparing a new updated national strategy are contemporary trends of the impacts of DFD in Australia and around the world. Such trends help identify where further opportunities lie to improve the foot health of people living with diabetes here in Australia and help focus advocacy efforts for positive national change. Thus, in informing the development of this new strategy, the national strategy sub-committee reviewed the latest evidence on the impacts of DFD in Australia and around the world.

“

What **must also be considered in preparing a new updated national strategy are contemporary trends of the impacts of DFD in Australia** and around the world. Such trends help identify where further opportunities lie to improve the foot health of people living with diabetes here in Australia and help focus advocacy efforts for positive national change.

## SECTION 2

# THE LATEST IMPACTS OF DIABETES-RELATED FOOT DISEASE

## DFD is a large cause of the world's total disease burden

Globally, DFD is estimated to affect 199 million people and cause 1.8% of the total global disease burden.<sup>10,16</sup> This makes DFD the 13th largest cause of the global disease burden or world's health problems (Figure 3).<sup>10,11,17</sup> Indeed, the disease burden caused by DFD is similar in size to the dementia and breast cancer combined and is the largest cause of the diabetes disease burden.<sup>10,11,17</sup> Yet, unlike these conditions, the disease burden from DFD is made up mostly of its disability burden, rather than its mortality burden,<sup>10,16</sup> and this is driven by DFD being a leading cause of poor quality of life, hospitalisation, and amputation.<sup>18,19</sup> Its mortality burden though cannot be overlooked, considering 5-year mortality rates for people with DFD are higher than for those with most cancers.<sup>20,21</sup> Thus, DFD is now one of the largest causes of the global disability (11th), mortality (21st), and total disease burdens (13th).<sup>10</sup>




Figure 3 Largest causes of global disease burden

In Australia, DFD is currently estimated to affect 510,000 people and cause 47,100 hospitalisations, 6,300 amputations, 2,500 deaths and cost \$2.7 billion each year (Figure 4).<sup>21-27</sup> This makes DFD the largest cause of hospitalisations, amputations and disability burdens in people with diabetes in Australia.<sup>7,11,26,28,29</sup> Indeed, hospitalisation rates for DFD (25 hospitalisations per 1,000 person-years with diabetes (25/1,000)) are much higher than that for heart failure (13/1,000), myocardial infarct (8/1,000) and stroke (6/1,000) in people living with diabetes.<sup>18,24,26</sup> Furthermore, Australians with DFD also have poorer mean quality of life (0.54; 0=death to 1=perfect health) than that for heart disease (0.77), cancers (0.75) and kidney disease (0.70).<sup>19,28,30</sup> Thus, DFD affects ~2% of all Australians and causes worse quality of life,<sup>28</sup> and higher chances of hospitalisation,<sup>31</sup> amputation and disability than much more well-known diseases in Australia.<sup>24,26</sup>

Each year in Australia it's estimated that

- 510,000** people are living with diabetes-related foot disease
- 47,100** hospitalisations are caused by diabetes-related foot disease
- 6,300** people will undergo an amputation because of diabetes-related foot disease
- 2,500** people will lose their life due to diabetes-related foot disease
- 2.7 billion** is spent in the Australian Health System for treating diabetes-related foot disease


Figure 4 Estimated people affected, hospitalisations, amputations, deaths and costs from DFD each year in Australia



## DFD is a growing cause of the world's total disease burden

Globally, the total global disease burden caused by DFD has grown substantially this century, even after adjusting for changes in the age structure of populations over this time.<sup>10,11,16</sup> Indeed, DFD has had the 4th largest increase of the top-30 largest conditions causing the global disease burden with most other conditions actually reducing in size.<sup>10,11,16</sup> Promisingly though, global major amputation (above ankle) rates caused by DFD have decreased during this century,<sup>10,18</sup> but minor amputation (below ankle) rates have increased,<sup>10,18</sup> and DFD-related hospitalisation rates are concerningly very high.<sup>18,24,26</sup>

Australia has substantially reduced its major amputation rates caused by DFD this century, and has improved from having the 2nd highest (in 2007) to the 8th lowest (in 2021) national major amputation rates of 35 developed countries according to the Organisation for Economic Co-operation and Development (OECD).<sup>32-37</sup> Indeed, major amputation rates have now decreased in Australia to very low rates of 0.6 per 1,000 person-years with diabetes, and much lower than the median global rate (0.9/1,000).<sup>18,24,26</sup> This is a significant national achievement, although it is noted this reduction is not consistently reflected across the country with major amputation rates continuing to be much higher for geographically remote and Aboriginal and Torres Strait Islander populations.<sup>38-40</sup> Concerningly though, minor amputation rates in Australia have increased to 2.9 per 1000 persons-years with diabetes, and much higher than the median global rate (1.4/1,000).<sup>18,24,26</sup> Furthermore, DFD-related hospitalisation rates have also substantially increased to 24.8 per 1,000 person-years with diabetes, again much higher than the median global rate (16.6/1,000).<sup>18,26</sup> Unfortunately, this has been a major driver in Australia deteriorating from having the 3rd lowest (in 2007) to the 4th highest (in 2021) national diabetes-related hospitalisation rates in developed countries according to OECD rankings.<sup>35,36</sup>



**Figure 5** How well Australia is doing for DFD in 2025 compared to other developed countries

Finally, the demographics of those affected by DFD are also changing. Globally, the DFD demographic has been mostly middle-aged and male, but increasingly getting younger as people are diagnosed with diabetes younger and living longer.<sup>11,16,18</sup> In Australia, the most rapid increases in DFD burdens have also been reported in those of younger ages and males.<sup>24,26,41,42</sup> For example, over the last decade in Australia, annual increases have been most marked in younger age groups (<40 years vs >80 years) for amputation (7.9% vs 0.5%) and hospitalisation rates (6.0% vs 2.4%), and in males for amputation (3.3% vs 1.9%) and hospitalisation rates (5.3% vs 2.7%).<sup>24,26</sup>

Thus, the DFD burden is growing in Australia, driven mainly by hospitalisations and minor amputations, and more of this DFD burden is shifting to younger male populations and away from older aged populations.

## Latest Australian DFD burden estimates

In Australia each year, latest estimates indicate that DFD affects 510,000 people and causes 47,100 hospital admissions (37,650 public, 9,450 private admissions), 6,300 amputations (5,250 minor, 1,050 major amputations), 2,500 deaths, and costs the Australian health system \$2.7 Billion.<sup>21-27</sup> Table 1 displays these estimates for an average year for the whole nation and per 100,000 Australian residents. Therefore, cities or regions can apply these per 100,000 estimates to their residential populations to estimate their local DFD burdens. For example, a city with a population of ~450,000 residents would multiply the below per 100,000 estimates by 4.5 to provide realistic estimates for their city. Thus, using the figures in Table 1, we can estimate in a city with a population of ~450,000 residents, DFD will impact around 8,500 people, cause 783 hospital admissions, 105 amputations, 42 deaths and cost the health system around \$44.8 Million in total direct costs to treat annually.

**Table 1** Estimated burden caused by DFD on Australia and per 100,000 Australian residents each year (see Appendix 2 for detailed explanations of all estimates in this table)

Characteristic	Australia <sup>a</sup>	Per 100,000 <sup>b</sup>
<b>Populations</b>		
People with diabetes <sup>c</sup>	1,500,000	5,556
People with DFD <sup>d</sup>	510,000	1,889
People with active DFD <sup>e</sup>	51,000	189
People with diabetes-related amputations <sup>f</sup>	25,000	94
<b>Hospitalisations</b>		
People in a hospital bed because of DFD <sup>g</sup>	471,000	1,744
Public Hospital	376,500	1,394
Private Hospital	94,500	350
People newly admitted to hospital because of DFD <sup>h</sup>	47,100	174
Public Hospital	37,650	139
Private Hospital	9,450	35
<b>Amputations</b>		
People undergoing an amputation because of DFD <sup>i</sup>	6,300	23.3
Public Hospital	5,250	19.4
Private Hospital	1,050	3.9
People undergoing a minor amputation because of DFD <sup>j</sup>	5,250	19.4
Public Hospital	4,350	16.1
Private Hospital	900	3.3
People undergoing a major amputation because of DFD <sup>k</sup>	1,050	3.9
Public Hospital	900	3.3
Private Hospital	150	0.6
<b>Mortality</b>		
Deaths from DFD <sup>l</sup>	2,500	9.3
<b>Costs</b>		
Total direct costs because of DFD <sup>m</sup>	\$2.69 Billion	\$9.96 Million
Hospital costs because of DFD <sup>n</sup>	\$1.09 Billion	\$4.04 Million
Primary care and other recurrent health costs because of DFD <sup>o</sup>	\$1.60 Billion	\$5.92 Million

## Latest Australian DFD burden that could be prevented with better care

A number of Australian cost-effectiveness analyses have consistently demonstrated that up to \$2.7 billion can be saved over five years (~\$10,000 per patient) for the Australia health system, if earlier access to guideline-based care is implemented for people with DFD across Australia.<sup>27,43,44</sup> These cost-savings are in addition to demonstrated health gains in quality of life and substantial reductions in the risk of hospitalisation and amputation for persons living with DFD.<sup>27,43,44</sup>

While the previous cost-effectiveness analyses relied on retrospective data and health economic modelling,<sup>27,43,44</sup> a recent Queensland Health report evaluated the cost-effectiveness of a real-world, state-wide, ~\$5 million annual funding model that incentivised earlier access to interdisciplinary high risk foot services (iHRFS) care across Queensland compared to usual access.<sup>45</sup> Using real-world data, the report found significant improvements in quality of life, plus significant reductions in hospitalisations, amputations, and costs per patient, and importantly a return on investment of \$8 for every \$1 invested in earlier access to iHRFS.<sup>45</sup> Thus, Australian health economic evidence now clearly demonstrates from a health system perspective that investing in better care for people with DFD generates substantially reduced health costs for nations, considerably improved health gains for patients, and substantial returns on investments for governments.<sup>27,43-45</sup>

Table 2 uses this Australian health economic evidence to forecast the health gains and cost savings available if guideline-based care is systematically implemented across the nation for all Australians with DFD. These forecasts suggest that every year in Australia we could prevent 188,400 people from being in a hospital bed, 20,250 new hospital admissions, 2,840 amputation procedures, 1,125 deaths and \$0.94 Billion dollars in costs by systematically implementing guideline-based care for people with DFD across Australia (or 698 hospital beds, 75 new hospital admissions, 10 amputations and \$3.48 Million every year for each average region of per 100,000 Australian residents). This is the equivalent of freeing up an entire 500+ bed hospital in Australia each year and demonstrates why a nationwide strategy is urgently needed to improve health service delivery for people with DFD in Australia.

**Table 2** Forecasted savings if guideline-based care for people living with DFD is systematically implemented across Australia and per 100,000 Australian residents (see Appendix 2 for detailed explanations of all estimates in this table)


Characteristic	Australia <sup>a</sup>	Per 100,000 <sup>b</sup>
<b>Morbidity savings</b>		
People prevented from being in a hospital bed <sup>c</sup>	188,400	698
People prevented from being admitted to hospital <sup>d</sup>	20,250	75
People prevented from undergoing an amputation <sup>e</sup>	2,840	10.5
<b>Mortality savings</b>		
People prevented from dying <sup>f</sup>	1,125	4.2
<b>Cost savings</b>		
Costs prevented to health system <sup>g</sup>	\$0.94 Billion	\$3.48 Million

## Methodology

This **Australian Strategy for Foot Health and Disease in Diabetes 2030: improving the foot health of people living with diabetes** has been developed by the National strategy subcommittee of DFA. The subcommittee was commissioned by the DFA Steering Committee following a day long strategic planning day, and membership comprised experts from multiple health disciplines, including people with lived experience and Aboriginal and Torres Strait Islander people.

The subcommittee worked from a general methodological framework agreed to by the DFA Steering Committee. Firstly, the subcommittee were asked to review developments since the inaugural national strategy via the national report card and a contemporary analysis of the latest national impact of DFD. Secondly, the subcommittee were asked to align the new strategy with key principles and enablers developed by the steering committee and considered important to diabetes foot health. Thirdly, the subcommittee were then asked to propose, develop, discuss, and agree via consensus on overarching priority areas, key goals, potential areas for action and measures of progress to achieve those goals by 2030. The overarching priorities and accompanying key goals were largely maintained from the inaugural strategy with minor modifications. Finally, public consultation was undertaken where any members of the public were invited to provide feedback, all feedback was considered and where relevant addressed to develop this final version.

The framework for the Australian Strategy for Foot Health and Disease in Diabetes 2030: improving the foot health of people living with diabetes, including principles, enablers, and priorities is depicted in Figure 1. The framework aims to promote the person with diabetes as the central and most important part of the strategy, surrounded by the overarching priorities and all underpinned by the key principles and enablers.



**Figure 6**  
The framework for the Australian  
Strategy for Foot Health and Disease in  
Diabetes 2030: improving the foot health  
of people living with diabetes



# Principles

## Equity

Equity in healthcare ensures that all people have a fair opportunity to attain their full health potential and have fair access to the health services and resources they need.<sup>46</sup> Equity fosters a more inclusive and just healthcare system and is an important principle for people living with diabetes with, or at risk of DFD. In Australia there are significant challenges to ensuring equitable health care. For example, First Nations Peoples require access to culturally safe health care to best enable health and wellbeing. The current Australian mainstream healthcare model is often not culturally safe, denying Aboriginal and Torres Strait Islander people the opportunity to maintain or improve their health and quality of life.<sup>47</sup> The geographical scale of Australia also influences equity in access to health care for those in non-metropolitan areas, especially rural and remote areas.<sup>48</sup> Furthermore, Australia should also aim to promote equity in healthcare for our Western Pacific region, by collaborating with regional partners, sharing educational resources, promoting best practice, and helping develop innovative solutions to address local challenges in DFD care. Australia's strong healthcare system and expertise in DFD offer significant opportunities to support not only regions in our own country, but neighbouring countries through training programs, educational initiatives, and collaborative research. Thus, proactive and innovative approaches to equitable foot health care for people living with diabetes is needed across our communities, nation and region, especially due to the complex nature of DFD and the multidisciplinary care required.<sup>49</sup>

## Shared responsibility

Shared responsibility recognises the need for the active participation of all parties involved with a person's health care. While health professionals, family/carers and community resources all play a key role in maintaining or improving foot health, the most important person is the person living with diabetes themselves. This has been particularly highlighted in diabetes foot health for decades, as maintaining foot health requires a person living with diabetes to constantly make lifestyle and self-care decisions to maintain their own health. Diabetes foot health is often an underappreciated but significant part of a person's overall health, and education and support are key requirements for individuals and the community to understand its significance. Further developments are required to explore the efficacy of a range of potential initiatives to support shared responsibility and in turn to support a person living with, or at risk of DFD. This could include access to health education and information, support for interventions to optimise self-care behaviour, peer support programs and collaborative patient/ consumer involvement in health care design and improvement.

## Evidence-based

Evidence-based approaches to health care involve integrating the best available evidence with clinical expertise and patient preferences to ensure that interventions and practices are both effective and relevant.<sup>50</sup> DFA strongly promotes this principle and has recently demonstrated it in the development of the suite of Australian evidence-based guidelines for those at risk of or with DFD. Although there have been significant advances in Australian DFD research, DFA acknowledges the continuing and disproportionate impacts of DFD on First Nations Peoples, and the urgent need for culturally responsive DFD research to be undertaken with and for Aboriginal and Torres Strait Islander people. Research evidence collected using and valuing Indigenous methodologies is essential to providing culturally responsive care and redressing severe disparities in DFD outcomes currently experienced by Aboriginal and Torres Strait Islander people.

## Enablers

### Advocacy

Advocacy involves actively supporting and promoting the rights, needs, and interests of patients and communities to ensure they receive equitable, evidence-based, and shared compassionate care.<sup>51</sup> The Australian DFD community is active and passionate with regards to advocacy and will continue to inform policy makers and resource holders about the nature of DFD, the impact it has on people and health systems, and to provide equitable, evidence-based, and practical policy advice to improve the foot health of people living with diabetes. In addition to these continued efforts, it is particularly important that advocacy efforts for people with DFD focus on Federal and State Government health policies to address current key deficiencies such as research funding, access to preventative care, access to all care in regional and rural communities, workforce shortages and implementation of culturally responsive care across Australia. Unfortunately, the ability for effective advocacy is limited, as DFD advocacy bodies are largely organised by volunteers with minimal resources. Thus, it is important that these bodies continue to be supported by the community and resourced by government to effectively advocate for the 510,000 people living with DFD.

### Funding and resources

A crucial aspect of funding and resources is the proportionate distribution of available Australian healthcare resources to address the proportion of the overall Australian disease burden caused by a condition (such as DFD), while also addressing the disparities in different communities and regions.<sup>52</sup> As demonstrated in earlier sections, the current impact of DFD in Australia is significant and causes a substantial proportion of the Australian disease burden, yet current healthcare resourcing to address such a substantial disease burden is disproportionately low compared to other much more well-known conditions with much lower disease burdens. This disproportionality of funding and resourcing for DFD seems to be systematic across all health services, public health programs, and research and development and needs to be significantly increased across the board to equitably address the proportionate disease burden caused by DFD on Australians and Australia.

### Workforce

An appropriate healthcare workforce is crucial for delivering culturally responsive, high-quality, and effective care for any condition. This involves ensuring the workforce is appropriately funded and resourced, well-trained, competent, and has the capacity to meet the diverse needs of people with the condition. People with diabetes or DFD need access to a workforce that can perform evidence-based screening, preventative footcare and management of DFD. Thus, people with DFD require a multi-disciplinary workforce, possibly more so than any other condition,<sup>49</sup> with multiple disciplines sharing their expertise to provide best DFD evidence-based care and outcomes. An appropriate evidence-based workforce for the care of people with DFD typically should include medical, surgical, nursing, and allied health disciplines working together with the person with DFD (and their family and carers). Appendix 1 provides a summary of the health professional disciplines who are likely to be involved in the care of a person with DFD dependent upon their individual DFD needs.

An optimal multi-disciplinary workforce requires ongoing training to keep up with advancements in technical and cultural knowledge. Education is fundamental for ensuring that health professionals are equipped with the knowledge, skills, and competencies necessary to provide high-quality care. This should encompass formal undergraduate and postgraduate training programs, continuing education, and professional development opportunities. A culturally safe workforce is also an integral enabler to improved diabetes foot health. The Indigenous Allied Health Australia's Diabetes Foot Care model (commissioned by the Aboriginal and Torres Strait Islander Diabetes-Related Foot Complications Program) provides a good example of a workforce model that encompasses an appropriate cultural, clinical, social and emotional wellbeing, and health promotion workforce.<sup>53</sup>

Currently there is a considerable DFD workforce shortage across Australia and particularly in geographically regional and remote areas. Thus, there is a need for the development of a specific national DFD workforce strategy to map current and future DFD workforce capacity, skillset, needs and geographical distribution, across a range of relevant health professional disciplines, to improve and support future workforce planning across the country. Subsequently, targeted initiatives to facilitate DFD workforce expansion and development such as incentivised regional and remote pathways and placements and DFD focused graduate programs, could be explored.

Table 3 outlines the estimated full-time equivalent health professional and interdisciplinary high risk foot service (iHRFS) workforce required to ensure access to evidence-based care for all people with or at-risk of DFD across Australia each year and is potentially a good starting point for the consideration and development of such a national DFD workforce strategy.

**Table 3** Estimated full-time equivalent health professional and interdisciplinary high risk foot services (iHRFS) workforce required to ensure access to evidence-based care for people with or at-risk of diabetes-related foot ulcers across Australia each year (see Appendix 2 for explanation of citations in table)

Characteristic	Australia <sup>a</sup>	Per 100,000 <sup>b</sup>
<b>LEVEL 1 CARE Screening for all people living with diabetes</b>		
People with diagnosed diabetes <sup>c</sup>	1,500,000	5,556
Number of health professional consultations required to perform screening <sup>d</sup>	1,500,000	5,556
Number of FTE health professionals required to perform screening <sup>e</sup>	313	1.2
<b>LEVEL 2 CARE Prevention for all people at-risk of DFU</b>		
People at-risk of DFU <sup>f</sup>	510,000	1,899
Number of health professional consultations required to perform prevention <sup>g</sup>	2,040,000	7,556
Number of FTE health professionals required to perform prevention <sup>h</sup>	425	1.6
<b>LEVEL 3a CARE Care for all people with active DFD (inc DFU) in ambulatory settings</b>		
People living with active DFD <sup>i</sup>	51,000	289
Number of iHRFS consultations required to perform ambulatory care <sup>j</sup>	2,650,000	9,815
Number of FTE iHRFS required to perform ambulatory care <sup>k</sup>	550	2.0
<b>LEVEL 3i CARE Care for all people with active DFD (inc DFU) in inpatient hospital settings</b>		
People in a hospital bed because of DFD <sup>l</sup>	471,000	1,744
Number of iHRFS consultations required to perform inpatient care <sup>m</sup>	471,000	1,744
Number of iHRFS required to perform inpatient care <sup>n</sup>	64.5	0.2

## GOAL

### 1

All people living with diabetes need access to culturally responsive evidence-based annual screening to determine their risk of diabetes-related foot ulcers and inform their risk-based footcare

## Foot health screening to identify risk

Effective preventative care can greatly reduce the risk of diabetes-related foot ulcers (DFU).<sup>54</sup> Australian and International evidence-based guidelines strongly recommend all people living with diabetes receive an annual evidence-based foot screening by an appropriately trained health professional, to identify if they are at-risk of developing a DFU.<sup>55,56</sup> This includes at a minimum, screening for the presence of peripheral neuropathy and peripheral artery disease (PAD).<sup>55,56</sup> Foot screening informs an individual's needs for ongoing footcare and education that will most effectively reduce their risk of developing a DFU.<sup>55,56</sup>

More than 1.5 million people in Australia are estimated to be living with diabetes.<sup>25,57</sup> According to a recent 2023 clinic-based study of 1,084 people living with diabetes from 25 NADC accredited diabetes services, 68% of people reported having a foot screening in the past year.<sup>58</sup> This potentially suggests a modest improvement from the only previous estimates of 50% from an older population-based study,<sup>59</sup> although this improvement is still unclear as these estimates are from different study populations. The nature and extent of foot screening is also highly variable with large gaps found between screening practices in clinical practice and those recommended in guidelines.<sup>60</sup> However, in comparable countries, the establishment of national diabetes foot screening tools and programs have been shown to increase national screening rates to be inclusive of the vast majority of populations living with diabetes, whilst also importantly providing robust DFD prevalence data to inform both health policy and research priorities.<sup>61</sup> We suggest establishing similar national diabetes foot screening tools and programs in Australia would likewise substantially increase national foot screening rates, provide DFD prevalence data, improve access to effective preventive care for people living with diabetes and help direct national strategies to combat DFD.

## Culturally responsive evidence-based foot health screening

Access to a culturally responsive evidenced-based national foot screening program that is integrated with established community and hospital-based DFD care is a key initiative that will help support the health and wellbeing of people living with diabetes. The 2021 Australian evidence-based guidelines for the prevention and management of DFD ('the Australian Guidelines') highlight the need for careful consideration of strategies to improve footcare delivery for First Nations Peoples and for any people living in geographically remote areas – populations found to be more likely to experience the most severe outcomes of DFD and urgently require better access to culturally responsive care.<sup>38,40,62</sup> Recognising the considerations of the Australian Guidelines, the diversity and geographical scale of Australia, the limited workforce capacity in rural and remote areas,<sup>63</sup> and a colonial history that continues to drive health inequities for Aboriginal and Torres Strait Islander Peoples, such national foot screening programs require an evidence-based, contextually relevant and culturally responsive screening tool, and effective mechanisms to support and monitor implementation of such a tool.

Integral to effective and culturally responsive foot screening programs are fit for purpose foot screening tools that support equity of access to culturally responsive footcare and the differing needs of people living with diabetes in all geographical locations, including rural and remote settings. Commensurate with this, we firstly propose a culturally responsive foot screening and referral tool is developed using a First Nations-led co-design process ensuring First Nations leadership; a culturally grounded approach; respect; benefit to First Nations Communities; inclusive partnerships; and evidence-based decision-making.<sup>64</sup> We recommend this development is underpinned by latest evidence-based Australian Guidelines<sup>55</sup> and informed by existing tools, such as the FootForward screening tools. To support widespread implementation of this screening tool we also recommend development of a co-designed culturally responsive training package for health professionals to accompany the screening tool.



## Implementation of culturally responsive evidence-based foot health screening

To adequately provide the evidence-based foot screening recommended by the Australian Guidelines for the 1.5 million Australians living with diabetes,<sup>25,57</sup> we estimate the equivalent of 313 full time equivalent (FTE) health professionals are required in Australia, or 1.2 FTE per 100,000 Australian residents (see Table 3). Through implementation of a national culturally responsive foot screening program to determine the risk-based footcare needs of individuals living with diabetes we anticipate a more patient-centred approach to subsequent footcare provision can be achieved. For people with restricted care access, for example those living in rural and remote areas where care provision may not be available locally and for Aboriginal and Torres Strait Islander people for whom culturally responsive care may not be readily available, opportunistic or more frequent screenings may also be indicated.<sup>65</sup> Currently, diabetes foot screenings are being reimbursed under a range of general Medicare Benefits Schedule (MBS) items, while access to further assessment and treatment (e.g., with allied health professionals such as podiatrists) is allocated by the primary health provider rather than directed by the DFU risk status of the patient. We suggest creating a new MBS Item specifically for foot screening using the co-designed foot screening tool, to systematically identify those people at-risk of (or with) DFU as early as possible. Referral and access to services appropriate to the risk status of an individual can then be effectively facilitated (see Goals 2 and 3). This will not only improve future footcare for people living with diabetes, but it will also enable robust monitoring of diabetes foot screening rates across the country. We suggest that such newly created specific MBS item should be available for use by a range of appropriately trained health professionals. Any increased investment needed for the introduction of such a new foot screening MBS item would be modest, as it would likely involve a cost shift from a range of general MBS items currently being used to a specific MBS item for this purpose.

We recommend the criteria to receive reimbursement for such a new diabetes foot screening MBS item should include performing the aforementioned foot screening assessment using the co-designed foot screening tool, plus providing culturally responsive education on their identified level of DFU risk to the person living with diabetes and referring them to appropriate evidence-based services when needed. This requires people living with diabetes and primary care clinicians to be educated on the need to undertake this process and of the appropriate evidence-based services available to them. In addition, in accordance with recommendations made in the Australian guidelines for further objective vascular assessment in people living with diabetes and suspected PAD,<sup>66,67</sup> for these individuals we also recommend reimbursements be made available to appropriately qualified health professionals (e.g. podiatrists), for recommended additional existing vascular assessment MBS Items (e.g. items 11610, Ankle-Brachial Index, Doppler ultrasound, Toe pressure measurement).

**All people living with diabetes need access to culturally responsive evidence-based annual screening to determine their risk of diabetes-related foot ulcers and inform their risk-based footcare**

**GOAL**  
**1**

### progress since inaugural strategy

- Implementation of the FootForward Program, providing patient and health professional education on understanding foot risk, foot-health guides, and resources
- Publication of DFA Australian evidence-based guidelines for DFD informing evidence-based foot risk stratification tools and referral pathways

### potential areas for action

- Further develop and refine co-designed, culturally responsive, evidence-based foot screening and referral tools (and associated training packages) for people living with diabetes and their primary care health professionals, beginning with First Nations Peoples
- Establish a new specific MBS Item number for annual diabetes foot screening in line with Australian evidence-based guideline recommendations
- Make existing vascular assessment MBS items available to other appropriately qualified non-medical health professionals
- Implement public awareness campaigns to encourage people living with diabetes and primary care clinicians to initiate annual diabetes foot screening

### potential measures of progress

- Proportion of people living with diabetes receiving annual diabetes foot screening per diagnosed diabetes population
- Proportion of people living with diabetes at-risk of developing, or with, DFU receiving referrals to appropriate evidence-based culturally responsive footcare services
- Consumer and health provider evaluation of foot screening tool and health professional training packages

## GOAL 2

All people at risk of diabetes-related foot ulcers need access to recommended culturally responsive evidence-based preventative footcare from trained health professionals

### Culturally responsive evidence-based preventative footcare

All people living with diabetes that have peripheral neuropathy or PAD are at risk of developing diabetes-related foot ulcers (DFU).<sup>55,65,68</sup> Australian and International guidelines recommend these people at a minimum are at low risk of DFU and need evidence-based footcare consultations every 6-12 months with trained health professionals to prevent future DFU (i.e. 1-2 consultations per year).<sup>55,65,68</sup> The guidelines further recommend if these people also have foot deformities (including limited joint mobility, abundant callus or pre-ulcerative lesions, that further increase plantar pressures under their feet) their level of risk increases to being at moderate risk of DFU and they need more frequent evidence-based footcare consultations every 3-6 months (i.e. 2-4 per year).<sup>55,65,68</sup> Finally, guidelines recommend if people also have a history of DFU, amputations or end-stage renal disease their level of risk increases again to being at high risk of DFU and they again need more frequent evidence-based footcare consultations every 1-3 months (i.e. 4-12 each year).<sup>55,65,68</sup>

The culturally responsive and evidence-based footcare recommended to be delivered at each of these consultations is dependent on an individual's level of risk for DFU.<sup>55,65,68</sup> According to the guidelines, at a minimum, the components of this footcare should include: i) professional re-examinations for risk factors and DFU, ii) professional treatment of any pre-ulcerative foot lesions, callus and ingrown nails, and iii) education of patients on their risk level for developing DFU (low, moderate or high), the foot self-care they should enact (including daily inspections and wearing appropriate footwear) and how to seek urgent care for a DFU.<sup>55,65,68</sup> In those at moderate or high risk levels, this care should also include considerations to provide medical grade footwear, foot orthoses and/or digital flexor tenotomy surgery treatments to reduce high plantar pressure underneath the foot and in turn the risk of DFU.<sup>55,65,68</sup> However, in those with a history of DFU, these treatments become more important and are instead strongly recommended for health professionals to enact rather than just to consider.<sup>55,65,68</sup> Due to worse DFU outcomes for First Nations Peoples and non-Indigenous Australians living in rural and remote areas, access to culturally responsive preventative care commensurate with risk level for DFU for these populations should be prioritised. Therefore as for Goal 1, where there may be limited or inconsistent access to culturally responsive preventative care, opportunistic care access should be supported.<sup>65</sup> It should be noted that since the previous 2011 Australian DFD guidelines and previous 2018 Australian DFD Strategy,<sup>7,8,69</sup> these footcare recommendations have only become more specific and more strongly recommended based on additional research confirming the importance of this evidence-based footcare.<sup>55,65,68</sup>

Unfortunately, many components of this recommended evidence-based footcare are still not reimbursed via the MBS, Pharmaceutical Benefits Scheme (PBS) or other national funding schemes, such as the National Diabetes Services Scheme (NDSS), National Disability Insurance Scheme (NDIS), Department of Veteran Affairs (DVA), and private health insurance (PHI) schemes.<sup>34,55,65,68</sup> This is despite these components having been recommended for over ten years in all relevant guidelines and again in the latest Australian and International guidelines.<sup>34,55,65,68,70</sup> Examples of the footcare components not funded include medical grade footwear, which is now even more strongly recommended for people at high risk of DFU, based on several high-quality randomised controlled trials (RCTs) demonstrating significant reductions in the likelihood of developing DFU.<sup>5,34,55,65,68,70</sup> Furthermore, the number of evidence-based footcare consultations required to adequately examine and treat pre-ulcerative lesions at the frequency recommended to prevent DFU are still not reimbursed.<sup>34,55,65,68</sup> Depending on their level of risk, people at risk of DFU need between 1-12 footcare consultations per year as part of evidence-based footcare, to adhere to the recommendations made in latest Australian and International guidelines.<sup>55,65,68,69</sup> Such consultations are often provided by podiatrists, although other appropriately trained health professionals can provide them as well.<sup>55,65,68,69</sup>

However, such consultations still remain capped within the maximum number of five allied health professional consultations for non-Indigenous Australians (with an additional five visits available to First Nations Peoples) permitted per year for people with chronic conditions in the MBS.<sup>34,55,65,68</sup> This results in evidence-based footcare consultations for people at risk of DFU having to compete with other MBS allied health care requirements, be funded under other disparate national funding schemes or be funded by the patient themselves, all of which typically results in inadequate access to evidence-based footcare for people living with diabetes at risk of DFU.<sup>34,55,65,68</sup>

This lack of Australian Government reimbursement is striking, considering these evidence-based footcare treatments have been consistently recommended by Australian and International guidelines and are supported by robust high level evidence.<sup>55,65,68,69</sup> This failure to reimburse evidence-based footcare recommendations to prevent DFU has translated into a distinct lack of access to quality evidence-based footcare treatments for people at risk of developing DFU, the inevitable development or recurrence of DFU, and perhaps not surprisingly very high rates of hospitalisation in those with DFU in Australia, with hospitalisation for DFU now being the leading cause of Australia's comparatively very high national diabetes-related hospitalisation rates.<sup>18,24,26</sup>

## Facilitating culturally responsive evidence-based preventative footcare

We strongly call on the Australian Government to urgently rectify this obvious gap in care for people at risk of DFU by reimbursing all evidence-based care recommended in Australian evidence-based guidelines for people living with diabetes via MBS, PBS or similar national publicly-funded schemes (such as the NDSS, NDIS, and DVA). This would mean that access for all people living with diabetes to all the evidence-based footcare that they need is provided in accordance with Australian evidence-based guidelines for people with diabetes. Furthermore, for people at risk of or with DFU, multiple Australian cost-effectiveness studies have found that such access not only reduces incidence rates of DFU, hospitalisations and amputations, but is also cost-saving to the patient and the health system even after investing in this extra recommended evidence-based footcare.<sup>27,43-45</sup> To adequately provide the evidence-based footcare recommended in the Australian guidelines for the 510,000 Australians estimated to be at risk of DFU, we estimate the equivalent of 425 FTE health professionals are required in Australia, or 1.6 FTE per 100,000 Australian residents (see Table 3).

With the majority of appropriately trained foot health professionals that are able to provide this evidence-based footcare practicing in the private or not-for-profit sector (e.g. 80% of registered podiatrists practice privately<sup>71</sup>), reimbursements from MBS, PBS or other similar national schemes (such as NDSS, NDIS, DVA, and PHI) is vital in the care of people at risk of developing DFU. To ensure increased access to evidence-based care and prevent uncontrolled reimbursement claims, we recommend that only people with confirmed risk factors for developing DFU be eligible for reimbursement (see criteria recommended for new MBS item for diabetes-related foot screening in Goal 1). Furthermore, we recommend that only health professionals who can demonstrate to be appropriately trained in evidence-based footcare to prevent DFU are eligible for reimbursement of any new MBS, PBS or similar national publicly-funded scheme items in this area (see further Goal 4). Similar DFU reimbursement systems have been in place in Germany and Belgium for over ten years, and this has led to health professionals consciously choosing to either treat people at risk of DFU in accordance with evidence-based guideline recommendations, or refer to others that do.<sup>72</sup> In addition, for First Nations Peoples and geographically remote people, we again also recommend that access to translation services and options to conduct evidence-based footcare in shared medical appointments or in conjunction with the telehealth services be supported to increase the accessibility and cultural responsiveness of services. Finally, further reimbursements could be tied to demonstrated improved DFU clinical performance and outcomes achieved by health professionals (see further Goal 5).

GOAL  
**2**

**All people at risk of diabetes-related foot ulcers need access to recommended culturally responsive evidence-based preventative footcare from trained health professionals**

**progress since inaugural strategy**

- Publication of DFA Australian evidence-based guidelines for prevention of DFU
- Otherwise, limited progress has been made since the last strategy

**potential areas for action**

- Establish MBS, PBS or similar national publicly-funded scheme item numbers (such as NDSS, NDIS and DVA) to reimburse footcare consultations for all people at risk of DFU in line with Australian evidence-based guideline recommendations
- Establish MBS, PBS or similar national publicly-funded scheme item numbers to reimburse medical grade footwear and foot orthoses for all people at high risk of DFU in line with Australian evidence-based guideline recommendations
- Implement public awareness campaigns to encourage people living with diabetes and primary care clinicians to initiate preventative diabetes footcare, including preventative footwear

**potential measures of progress**

- Increased proportion of additional MBS, PBS or similar national publicly-funded scheme item number reimbursements for footcare consultations per estimated population at risk of DFU
- Increased proportion of additional MBS, PBS or similar national publicly-funded scheme item number reimbursements for medical grade footwear and foot orthoses per estimated population at risk of DFU

## GOAL 3

All people with active diabetes-related foot disease need access to clinically safe and culturally responsive evidence-based healthcare from interdisciplinary High Risk Foot Services

### Interdisciplinary High Risk Foot Services in Australia

Australian and International guidelines recognise that optimal care for people with active DFD requires a breadth of clinical skills possessed by no single healthcare discipline.<sup>49,55,56,73,74</sup> Active DFD includes ulceration, infection, ischaemia or active Charcot neuro-osteopathy of the foot in a person with diabetes.<sup>9</sup> People with active DFD need access to regular evidence-based care that requires clinical skills in the assessment and management of metabolic, vascular, neurological, orthopaedic, biomechanical, ulcer and infection aspects of DFD.<sup>49,56,67,73-84</sup> For this, collaborative patient-centred care should be provided by a range of clinicians with these different skills working together in specialised interdisciplinary High Risk Foot Services (iHRFS). Implementation of iHRFS have been found to significantly improve clinical and financial outcomes including hospitalisation and amputation.<sup>27,43,56,74,85</sup> Thus, it is vital that all Australians with active DFD have access to evidence-based healthcare from iHRFS in order to achieve optimal health outcomes.<sup>49,56,67,73-84</sup>

The exact number of iHRFS in Australia is currently unknown and heterogeneity in the availability, composition and function of iHRFS in Australia has previously been described.<sup>86</sup> However, since the release of the previous DFA strategy, there has been significant progress in defining the personnel, equipment, processes and procedures needed for an iHRFS in the Australian context with the release of the NADC iHRFS standards and accreditation program which outline the characteristics of a Core and a Centre of Excellence level iHRFS (see Goal 4).<sup>87</sup> Thus far, 17 iHRFS have been awarded accreditation as Centres of Excellence and 19 others accredited at Core level. Based on this information and canvassing DFD health professional networks in Australia we estimate there are currently approximately 70 iHRFS (including both accredited and non-accredited services) in Australia. Furthermore, most iHRFS in Australia are located in state funded ambulatory health care facilities such as hospital outpatient clinics or community health centres. However, to provide evidence-based interdisciplinary specialist care to the estimated 51,000 people with active DFD each day in Australia, we estimate the equivalent of 550 ambulatory iHRFS are required, or 2 ambulatory iHRFS per 100,000 people (see Table 3). In addition, we estimate the equivalent of 64.5 inpatient iHRFS are required in Australia, or 0.2 inpatient iHRFS per 100,000 people, to adequately care for the estimated 1,290 Australian inpatients in hospital each night with active DFD (Table 3). Thus, we suggest Australia has less than 15% of the iHRFS needed to adequately provide evidence-based care to all Australians with active DFD. Although this is an increase from the previous strategy estimate of having less than 10% of iHRFS needed, iHRFS availability needs to increase significantly and rapidly in Australia.

Improved outcomes, including reduced hospitalisation and amputations, have been achieved in Australian regions which have invested in improved access to iHRFS for people with active DFD.<sup>29,85,88</sup> NSW has invested in at least one iHRFS clinic per local health district and has achieved lower amputation rates in rural and regional areas than most other states.<sup>88</sup> In Queensland, investment in increased numbers of iHRFS across the state including in regional centres, has been associated with a 40% reduction in DFD hospitalisations, 45% reduction in major amputations and a 37.5% reduction in minor amputations.<sup>85</sup> Furthermore, data from the UK National Diabetic Foot Audit has demonstrated more rapid access to specialist care in iHRFS clinics is associated with higher likelihood of being alive and ulcer free at 12 and 24 weeks after DFU onset.<sup>89</sup>

In addition, Australian data has shown that a patient's location (distance from an iHRFS clinic) is a determinant of DFU healing outcomes, with a greater distance from an iHRFS clinic being associated with slower DFU healing and higher risk of amputation.<sup>48,90,91</sup> There can be challenges in recruiting an appropriately skilled workforce to staff iHRFS clinics in some regions, and greater efforts and access to training, upskilling opportunities and connection to established iHRFS will be important to help resolve these issues (see Goal 4). The marked increase in iHRFS required to meet current clinical needs will require substantial initial investment from State and Federal governments. However, as per aforementioned findings from Australian cost-effectiveness analyses studies,<sup>27,43-45</sup> even after accounting for initial investments to ensure access to evidence-based care for all Australians who need it, savings in the order of \$940 million per year (or \$3.5 million per 100,000 Australian residents each year) can be achieved (see Table 2). These cost savings, along with the significant improvements in patient outcomes, provide compelling justification for governments to facilitate the establishment of many more iHRFS.<sup>27,43-45</sup> This could be done through innovative incentives for public or conjoint public/private health services to establish iHRFS to cover staff, facilities and consumables.



## Facilitating care for people with active DFD across Australia

Providing timely access to iHRFS care is highly challenging in geographical areas of Australia with vast distances between health services and smaller populations. Telehealth should be facilitated and reimbursed between health professionals in rural and remote areas, with iHRFS in regional or metropolitan hubs. Several randomised controlled trials (RCT) of telehealth iHRFS models (consisting of initial iHRFS in-person assessment plus follow-up telehealth care by the iHRFS) compared with standard iHRFS in-person care in different European countries have consistently demonstrated similar outcomes for healing and amputation rates in those with DFU, but with potentially cost-savings for the telehealth iHRFS models.<sup>92-94</sup> A telehealth program for DFU and leg ulcer management was also associated with reduced diabetes-related amputations in Western Australia<sup>95</sup> and have now been funded with similar anecdotal improved outcomes in Queensland, NSW and South Australia.<sup>96,97</sup> There has also been recent telehealth acceptability and feasibility data from SA and for First Nations Peoples.<sup>98</sup>

To help support the expansion of innovative and evidence-based iHRFS delivery of care via telehealth of people with active DFD, this recommendation could be incorporated into existing telehealth MBS item numbers. To increase the number of ambulatory, inpatient and telehealth services provided by iHRFS in Australia, there is also a need to train many more multi-disciplinary health professionals to deliver the required iHRFS specialised care in both state-funded public facilities (for example public hospitals or community health care facilities) and MBS-reimbursed private facilities (for example private hospitals or large GP clinics) (see Goal 4).

Ongoing impacts of colonisation and persisting racism have contributed to First Nations Peoples experiencing a 3 to 6 fold increase in DFD rates compared with non-Indigenous Australians.<sup>40,99,100</sup> Access to evidence-based, culturally appropriate footcare services for Aboriginal and Torres Strait Islander people is essential to improving foot health and reducing the impacts of DFD.<sup>101</sup> Innovative models of care that are First Nations-led, address Community identified priorities, incorporate Indigenous knowledges and build trust between Community, Aboriginal Community Controlled Health Organisations (ACCHOs) and mainstream health providers (e.g. iHRFS)<sup>101</sup> need to be much more widely available. There are small scale examples both in Australia and internationally of initiatives to decolonise health care systems and provide culturally safe services to First Nations Peoples with diabetes and/or DFD.<sup>101-103</sup> Such services demonstrate that using First Nations-led service delivery models co-designed with and for First Nations Peoples and involving culturally capable health professionals and service delivery methods (e.g., clinical yarning and shared medical appointments) increases uptake of services and may in turn improve footcare management and DFD outcomes. Co-design of services for the management of active DFD must privilege First Nations health knowledges and priorities, re-position power to First Nations Peoples and be adequately supported through designated funding for and commitment to authentic First Nations-led co-design process and culturally safe and on Country care delivery.<sup>64</sup>

Since the first DFA strategy, the federally funded Aboriginal and Torres Strait Islander Foot Complications Program coordinated by the South Australia Health and Medical Research Institute (SAHMRI) was established. The program's aim was to improve foot health and reduce amputation rates for Aboriginal and Torres Strait Islander people living with diabetes in South Australia, the Top End of the Northern Territory and Central Australia, the Kimberley region in Western Australia and Far North Queensland.<sup>104</sup> The initial planning phase of the program investigated and reported on the determinants, burden and impact of DFD, as well as mapped available DFD services, and identified gaps in the system. Each region then developed an implementation plan to improve access to iHRFS care, optimise continuity of care, develop new service models, and enhance the existing workforce capacity and capability. This program has had a strong focus on community engagement and empowering people living with diabetes and those with or at risk of developing DFD to maintain healthy feet, recognise foot health risks early and navigate the health system to access early and appropriate care. A formal evaluation of the program has not yet been published, but anecdotally it has been a success, and such successful initiatives will require ongoing financial support.<sup>104</sup>

Similar to prevention (see Goal 2), there is a lack of reimbursement via MBS, PBS and national schemes (such as NDSS, NDIS, DVA and PHI) for many Australian guideline recommended evidence-based care components necessary to treat people with active DFD.<sup>34</sup> For example, the frequent (weekly or fortnightly) podiatry consultations required to adequately treat active DFD and the provision of necessary pressure offloading devices are not reimbursed via MBS or PBS.<sup>55,56,76,78,80,81</sup> In terms of optimal DFD outcomes, necessary offloading devices (such as non-removable moonboots) to heal active DFU have amongst the highest level of evidence and strength of recommendation of all Australian diabetes-related guideline recommendations.<sup>55,56</sup> Additional barriers to access such necessary offloading devices include geographical inequity of access, workforce constraints and suboptimal awareness and education regarding the importance of these evidence-based interventions.

Australia's healthcare system includes both public sector and private health organisations with complex funding sources including Australian federal, state and territory governments, private sector service providers, not for profit organisations and individuals.<sup>105</sup> Most iHRFS in Australia are located in public hospitals. Further work should be undertaken to understand the barriers and facilitators to establishing iHRFS in the private healthcare setting, such as innovative funding models and MBS incentives. Without reimbursement for Australian guideline recommended evidence-based care<sup>34</sup> it is unlikely that many iHRFS will be established in the private sector and thus people with active DFD will nearly always need to seek care in the public health system.

However, there has been progress made in funding of wound care consumables for the management of DFUs since the previous Australian DFD Strategy with the 2023 announcement of the Australian Government funded Chronic Wound Consumables Scheme. This scheme will provide people living with diabetes aged 65 years and over and Aboriginal and Torres Strait Islander people aged 50 years and over access to subsidised wound consumables.<sup>106</sup> This funding investment should greatly improve access to affordable wound care management for many Australian's >65 years living with DFUs. However further funding is still required to ensure equitable access to wound consumables for all people living with DFUs, especially considering as outlined in Section 2 that demographic trends indicate many people with DFD are being diagnosed much younger (<65 years) and those of youngest ages (<40 years) are experiencing the poorest DFD outcomes.<sup>11,18,24,26</sup>

Finally, more work must be undertaken to better empower and inform communities of people living with diabetes regarding the evidence-based care they should expect to receive for management of active DFD. Since the first DFA strategy, there have been new patient and health professional focused educational resources developed by the NDSS Foot Smart program, the DFA Toolkit and associated educational materials, the DFA Foot Passport, the National Foot Forward program and also a number of resources developed in collaboration with community from the SAHMRI Aboriginal and Torres Strait Islander Foot Complications Program. These resources should continue to be disseminated as widely as possible via social media, patient organisations, peak national health professional organisations and governments. Furthermore, we strongly recommend there should be national public awareness campaigns and patient-friendly tools to encourage people with active DFD to seek early access to evidence-based care. Wounds Australia has recently been awarded a \$2 million federal government grant to deliver a national education and awareness campaign on chronic wound prevention and treatment.<sup>107</sup> which will go some way to helping to raise awareness of this problem in general, but much more needs to be done to raise awareness of the fact that people with DFU urgently need evidence-based iHRFS care.

GOAL  
**3**

**All people with active diabetes-related foot disease need access to clinically safe and culturally responsive evidence-based healthcare from interdisciplinary High Risk Foot Services**

### progress since inaugural strategy

- Gradual increase in numbers of iHRFS across Australia mainly via state government funding
- Improved funding and resources for iHRFS for Aboriginal and Torres Strait Islander people via the SAHMRI Aboriginal and Torres Strait Islander Foot Complications Program
- Australian Chronic Wound Consumables Scheme funding now available, but not all people with active DFD are eligible
- DFA, Foot Forward, DA, NDSS developed patient friendly tools for people with DFD
- Wounds Australia recently awarded funding for national education and awareness chronic wounds campaign
- No progress in coordinated national funding of iHRFS, including telehealth models

### potential areas for action

- Establish innovative incentives and funding model agreements to significantly increase the number of iHRFS in the public and private sector, including via telehealth
- Establish an MBS, PBS or similar national publicly-funded scheme item numbers (such as NDSS, NDIS and DVA) to reimburse offloading devices for all people with active DFD in line with Australian evidence-based guideline recommendations
- Consider tying ongoing reimbursement of iHRFS for active DFD care to improvements in regional clinical process indicators and outcomes
- Implement national public awareness campaigns and patient-friendly tools to encourage people with active DFD to seek early access to evidence-based care

### potential measures of progress

- Increased number and proportion of iHRFS available across Australia and in each health service region
- Increased proportion of people with active DFD treated in iHRFS
- Increased proportion of people with active DFD receiving appropriate offloading devices
- Increased proportion of people with DFU receiving appropriate wound dressings
- Increased proportion of people with active DFD receiving telehealth consultations with iHRFS
- Perform cost-effectiveness analyses of increased investments in evidence-based iHRFS compared to usual care for people with active DFD to determine and report on patient outcomes, costs and returns of investments in additional iHRFS across Australia

## GOAL

# 4

All people living with diabetes-related foot disease should have access to interdisciplinary High Risk Foot Services that meet evidence-based standards

## Accreditation of iHRFS

Considerable recent progress has been made in developing Australian standards for iHRFS and a robust national accreditation process for iHRFS has been established. The NADC formed a collaborative interdisciplinary Foot Network Working Party in 2017, which had broad representation across relevant health professions and 12 peak national health professional organisations. The working party developed and launched Australian iHRFS Standards in 2018, and reviewed and updated them in 2021.<sup>108</sup> The standards outline detailed service indicators for Core and Centre of Excellence iHRFS levels across 8 standard areas including interdisciplinary approach, governance, evidence-based management, access criteria, continuity of care, equipment, wound care, and quality improvement. In conjunction with the standards, the NADC implemented a world leading iHRFS Accreditation program in 2019.<sup>109</sup> To date, 17 services have been awarded Centre of Excellence status, 19 services awarded Core status, and 15 of those services have now completed reaccreditation (4 yearly assessment cycle). Nearly all accredited iHRFS are located in metropolitan or large regional cities. However, a dramatic increase in the number of appropriately skilled, well-organised and accredited iHRFS is still required to ensure all people with active DFD across Australia have access to the quality iHRFS footcare they require to achieve optimal health outcomes (see also Section 2 and Goal 3).

To build upon the considerable success of this leading iHRFS accreditation program, further development of the program could consider aspects such as the cultural responsiveness of the program, the potential reach and flexibility of the program to health services in diverse geographical areas and diverse populations, and the potential barriers to proceeding through the iHRFS accreditation process. For example, provision of evidence-based, culturally appropriate iHRFS care for Aboriginal and Torres Strait Islander people is essential to improving outcomes and reducing the impacts of DFD.<sup>101</sup> There are examples both in Australia and internationally of initiatives to decolonise health care systems and provide culturally safe services to First Nations Peoples with DFD, incorporating models of care co-designed with and for First Nations Peoples, and involving culturally capable health professionals and service delivery methods such as clinical yarning and shared medical appointments.<sup>101-103</sup> The current NADC iHRFS core standards do already emphasise the need for iHRFS to provide culturally appropriate care (standard 4, indicator 6). However future versions of the standards provide opportunities to expand this standard, by including collaboration with Aboriginal and Torres Strait Islander people and organisations, using First Nations-led approaches that reflect the immense diversity of First Nations Communities priorities, and supporting First Nations Community-led approaches to development of DFD service delivery. Such work would require appropriate investment in time and resources.

For rural and remote regions of Australia, flexibility is likely required for accreditation to be considered for the many iHRFS-type services provided in these regions. These services may not be able to comply with current core iHRFS standards because of the lack of available core iHRFS health professionals and treatment modalities in rural and remote regions. However, evidence is expanding regarding telehealth models of care for people living with DFD,<sup>92,94</sup> with an increasing number of iHRFS telehealth programs being developed around Australia.<sup>96,97</sup> An area of potential future development of the iHRFS standards and accreditation program would be to add specific service indicators for a third Telehealth iHRFS level, with specific evidence-based service indicators to ensure safe and effective use of telehealth for interdisciplinary DFD management. This may have further spin-off benefits in terms of developing national recommendations for markers of quality telehealth care provided across all levels of iHRFS and potentially improve and widen options to access best practice care via in-person and telehealth for all people with DFD across Australia.

Other options for the further development of the accreditation program could be mandatory regulation of iHRFS standards (eg via systems such as the National Safety and Quality Health Service Standards).<sup>110</sup> This could drive further engagement and provision of additional resourcing to help provide support for iHRFS to successfully meet Australian iHRFS standards and achieve accreditation. Now that Australian iHRFS standards, accreditation, data collection and benchmarking process are well-established, further development could include activities such as peer-review or in-person iHRFS auditing. In Germany, accredited iHRFS visit each other at least six monthly for peer-review auditing.<sup>72</sup> This generates unique learning opportunities, strengthens networks, and avoids the need for a separate arbitrary external auditing body. However, substantial funding and resources would be required to progress with peer-review or in-person auditing iHRFS accreditation in Australia.

## Health professional education and training

For all health professionals involved in supporting people living with diabetes to be appropriately trained, specific culturally responsive and evidence-based education modules for optimising diabetes foot health need to be developed, endorsed and readily available at minimal cost. These modules should address the skills required across the entire spectrum of foot health in diabetes (encompassing primary, secondary and tertiary care), align with Australian DFD guideline recommendations and be relevant for multiple health professional disciplines. This is particularly important where there is limited access to culturally responsive health services and a limited health workforce, as often seen in rural and regional Australia. Fortunately, considerable progress has already been made in the development of education packages from peak national organisations (such as DFA, ADS, NADC, DA and others) in providing an increasing volume of available educational resources on DFD for health professionals. To pick one example, the FootForward program has produced three freely available, evidence-based, educational modules regarding diabetes foot screening, PAD and peripheral neuropathy, with associated continuous professional development recognition. Furthermore, similar DFD training packages for Aboriginal and Torres Strait Islander Health Workers are also available through the FootForward program website.

Whilst there is an increased volume of existing training and education modules available, further work needs to be undertaken to evaluate these modules to see if they are effective and for which health professions they appeal. For example, ensuring culturally responsive education and training packages are available is crucial for uptake and training for certain health professionals such as Aboriginal and Torres Strait Islander Health Workers, who may find it challenging to engage with available education modules, or remote area nurses may not find current resources useful for their practical day-to-day clinical experiences. Most of these existing modules and resources though are targeted at GPs and primary care health professional level. Therefore, there is still much scope for the development of advanced DFD education modules targeted at early and mid-career health professionals across diverse disciplines, to support their development towards becoming more knowledgeable and skilled particularly in the area of active DFD care. This would in turn start to build health professional interest and capacity towards the optimal multi-disciplinary DFD workforce to ensure access to optimal care for all people with DFD across Australia as outlined in Table 3.

## Health professional credentialling

For practitioners working in iHRFS settings, there are some health professional discipline specific training and regulatory processes in place to try and ensure delivery of safe, quality care. For example, specialists such as vascular surgeons, endocrinologists and infectious disease physicians all complete advanced post-graduate training programs with curricula which may include the management of DFD. Specialist medical organisations also provide additional educational opportunities for doctors in training, such as the DFD education session comprising part of the 2-day ADS Practical Skills Course for 1st year endocrinology advanced trainees. Whereas university undergraduate podiatry programs also typically include dedicated units on DFD management of varying length and emphasis. However, there are no specific post-graduate qualifications or credentialling focused on DFD in any discipline, although podiatrists can pursue further qualifications in advanced prescribing, nurse practitioners can specialise in advanced wound care and a high quality of DFD footcare can be developed through supported experience and practice in hierarchical iHRFS teams.

Whilst additional certification, credentialling or accreditation of individual health professionals to ensure competency of practice in preventative and active DFD management was recommended in the first strategy and explored by some peak health professional bodies, this approach has not gained significant traction either in Australia or internationally at this stage. However, there could be better scope and appetite for a voluntary certification, credentialling or accreditation process for DFD health professionals at screening and prevention levels (e.g. in primary care with general medical practitioners, primary health care nurses, Aboriginal Health Practitioners or podiatrists), and active DFD management levels (e.g. in secondary and tertiary care, such as with iHRFS podiatrists, endocrinologists, vascular surgeons or nurse practitioners). This could have synergies with and potentially sit alongside the existing iHRFS accreditation process. Rather than mandating a set of core competencies or certification, the voluntary health professional credentialling/accreditation process could be a personal achievement, identifying an individual as providing excellent quality DFD screening, prevention and/ or care or lead to certain reimbursements and deserved consideration.



## Reimbursement

A possible long-term strategy for iHRFS accreditation is to align qualifications with reimbursement (see Goals 1–3). In Germany and Belgium, for example, only accredited iHRFS are eligible to receive public or private reimbursement when treating people with active DFD, which has been essential for the longevity of iHRFS.<sup>72</sup> Furthermore, if individual health professional credentialing/accreditation at each level of DFD care was progressed, this could also potentially be tied in future to eligibility for re-imbursement of specific MBS items, such as bedside vascular assessment, offloading device or wound dressings MBS items, which may increase the attractiveness to health professionals for such a quality improvement credentialing process.

### GOAL 4

**All people living with diabetes-related foot disease should have access to interdisciplinary High Risk Foot Services that meet evidence-based standards**

#### progress since inaugural strategy

- Australian iHRFS standards and accreditation process have been established by the NADC
- A public register of accredited iHRFS has been established & available on the NADC iHRFS accreditation website
- iHRFS benchmarking is now available via participation in standardised national DFD data collection and benchmarking process via the Australian Diabetes Foot Registry (see Goal 5)
- Multiple health professional education and training modules in DFD management developed by multiple national peak bodies across Australia

#### potential areas for action

- Consider mechanisms to support more services completing the iHRFS accreditation process
- Consider introduction of new iHRFS standards and accreditation processes for remote iHRFS, telehealth iHRFS and services providing care to First Nations people
- Raise awareness of existing evidence-based education and training modules for healthcare professionals working with people with, or at-risk of, DFD
- Develop new education and training modules aimed at health professionals working with people with active DFD
- Develop further undergraduate, postgraduate and advanced trainee DFD training options
- Develop a sustainable process for reviewing and endorsing iHRFS accreditation standards and DFD training and educational modules, to ensure they align with latest evidence-based guidelines and are accessible to all stakeholders
- Develop a new voluntary credentialing program for individual health professional to recognise their knowledge, experience and competency for 3 different levels of DFD care: screening, prevention and management of active DFD
- Align DFD reimbursement strategies with credentialing for individual health professional's and accreditation for iHRFS

#### potential measures of progress

- Increased number or proportion of iHRFS accredited
- Broadened iHRFS accreditation program to include diverse iHRFS services for diverse populations of Australia
- Increased number of education and training modules that are accessible, relevant, evidence-based and improve the foot health of people with diabetes.
- Establishment of a voluntary credentialing/accreditation program for individual health professionals

## GOAL 5

All health service regions should report their diabetes-related foot disease outcomes annually and contribute standardised data to a registry that enables benchmarking and collaboration

### The value of standardised data collection

Data collection, audit and benchmarking are integral to optimisation of healthcare delivery.<sup>110–112</sup> Understanding the characteristics of people who develop DFD and the nature of disease can inform service development and resource allocation. Further, monitoring process and outcomes enables identification of areas for quality improvement at both a service and public health level.<sup>110–112</sup> The International DFD guidelines recommends “auditing of all aspects of services to identify and address problems and ensure that local practice meets accepted standards of care”.<sup>56</sup> Following on from these International guidelines, the Australian DFD guidelines noted gaps in data availability across several footcare domains, impeding local capacity to comprehensively evaluate clinical management and outcomes.<sup>113</sup> Through a broader lens, a key goal of the current Australian National Diabetes Strategy 2021–2030 is to improve access of diabetes-relevant datasets, linkage across healthcare settings and to foster new knowledge from aggregate analysis.<sup>114</sup> Given the power of data to effect positive change it is crucial that data registries purposefully include priority populations, such as people living in geographically remote areas, and explore mechanisms to support inclusion of primary care outcomes. Furthermore, it is important that Aboriginal and Torres Strait Islander people and Communities are empowered by supporting the development of First Nations governed datasets that align with their self-determined goals for DFD while ensuring Indigenous data sovereignty, which is a national priority.<sup>115</sup>

The inaugural strategy identified the need for improved and cohesive data collection practices by services managing DFD.<sup>8</sup> A major success of the intervening years has been the increasing integration of data collection in clinical care, particularly in iHRFS. In large part this cultural shift was driven by the introduction of the NADC Australian iHRFS Standards in 2018, and in particular the need to meet the service indicators in Standard 8 that are dedicated to data collection and quality improvement.<sup>108</sup> Combining data-driven outcome monitoring with accreditation was also recommended by the inaugural strategy based on the success of European service models.<sup>8,72</sup> In seeking accreditation by the NADC, several Australian iHRFS requested centralised guidance and infrastructure be made available to alleviate the local burden of developing and implementing data collection. A minimum dataset was derived by interdisciplinary expert consultation and based on the DFA Australian Diabetic Foot Ulcer Minimum Dataset Dictionary.<sup>6</sup> Imperative to the widespread uptake of this standardised minimum dataset was the supported and somewhat flexible implementation of a commonly used, accessible and free electronic data collection platform.<sup>116</sup> The periodic aggregation of data collected from this platform now feeds the Australian Diabetes Foot Registry (ADFR). Since 2022 ADFR annual site reports have provided comparative site and national statistics for benchmarking and quality improvement.<sup>117</sup> The ADFR has since been growing exponentially and has attracted numerous invited presentations at key national and international conferences further strengthening iHRFS collaboration across the country. Additionally, the Queensland High Risk Foot Form (QHRFF) database has been active for over 15 years across Queensland. The QHRFF is now one of the largest DFD datasets in the world and has been widely used in national and international studies.<sup>90,91</sup> Considering the ADFR and QHRFF, Australia has become an international leader in DFD data collection and this strength should be maximised to ensure all health service regions have the means to report and compare their DFD outcomes.

### Ensuring the right data is collected in the right way

Another noteworthy development over this period was the establishment of patient-reported outcome measures (PROMs), including quality of life, within diabetes and DFD datasets. The Australian Commission on Safety and Quality in Healthcare recommends use of PROMs to bring lived experience to the forefront of care.<sup>118,119</sup> While value-based healthcare is universally desirable, the adoption of PROMs by iHRFS should certainly be prioritised, as has been exemplified by implementation of the Leading Better Value Care program in New South Wales since 2017.<sup>120</sup> Moving forward, the appropriateness of generic PROMs for people living with DFD, and their usability, validity and reliability in this clinical context, should be assessed. Incorporating or linking PROMs with existing Australian DFD datasets will enable more comprehensive evaluation of outcomes important to the person with DFD which may not be simply measured by ulcer healing, hospitalisation and/or amputation rates.<sup>121</sup>

National outcome reporting relating to care of people living with DFD, has historically been reliant on general health databases that are not specifically focused on DFD, such as standard Australian hospital admissions datasets. Whilst resulting epidemiological data is powerful in identifying DFD care priority areas, such as showing growth and variations in incidence or outcomes of diabetes and DFD,<sup>10,11,18,122</sup> explaining these variations between services or regions typically require availability of more nuanced data. Resourcing and processes of hospital admission data collection and analysis for DFD is relatively well established.<sup>18,26</sup> However, there is still a need to standardise hospital coding definitions and reporting standards nationally, if not globally, for DFD hospitalisations as has previously been performed for diabetes-related amputations. This is ever more important considering DFD has emerged as the leading cause of diabetes-related hospitalisation both nationally and globally.<sup>18,26</sup> In this context, hospitalisation avoidance has become a major focus of iHRFS and community care, and with that monitoring non-admitted care and primary care outcomes is equally important to provide potential data-driven explanations of variations between services and regions across Australia. To conceptualise integrated DFD data reporting systems needs in Australia, Table 4 outlines the general DFD outcomes of interest needed, along with the datasets available to inform those outcomes, and recommended actions to deliver reporting of those outcomes for each aspect of the Australian healthcare system.

**Table 4** DFD outcomes of interest, datasets available and recommended actions for data reporting systems in Australia

Healthcare system	Outcomes of interest	Datasets available	Recommended actions
Tertiary	Hospital admitted care process and clinical outcomes	Australian hospital admission datasets	National consensus standards on the definitions for identifying and reporting DFD hospitalisations
Secondary	Non-admitted care process and clinical outcomes	Australian Diabetes Foot Registry and Queensland High Risk Foot Form (QHRFF) Database	Increasing contribution of iHRFS to existing datasets / registries
Primary	Primary care process and clinical outcomes	Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS), and National Diabetes Services Scheme (NDSS) datasets	Insufficient and fragmented; need to be incentivised for DFD data collection (see Goals 1 to 3)
Primary, secondary and tertiary	Patient-reported outcome measures (PROMs)	Health Outcomes and Patient Experience platform in NSW and QHRFF in QLD	National consensus on PROMs for DFD, and standardised collection across states / territories
Aboriginal Community Controlled Health Organisations	Primary care and patient -reported outcomes for First Nations Peoples	MBS, PBS and NDSS; not otherwise standardised	Support First Nations Communities and Organisations to explore priorities and processes for data collection

The above table highlights the first challenge in addressing areas for action from the inaugural strategy, namely the siloing of data within different parts of the healthcare system. Australia is yet to realise a unified medical record system that caters to the needs of all states and territories, healthcare settings, health professionals, and patients across the whole system. As a result, standardising collection of DFD specific data are typically confined to state,<sup>123,124</sup> region<sup>41</sup>, healthcare setting<sup>125</sup>, or indeed service. Positively, the Australian Commission on Safety and Quality in Healthcare has published a revised framework to guide development of “future-focused” national clinical quality registries.<sup>126</sup> Beyond the logistics of implementing national data collection, reaching unanimous agreement on the dataset/s itself, can be challenging. Services also struggle with the time-demand of data collection when it is independent of routine clinical workflow, despite there being acknowledged ultimate benefits of this data reporting. Thus, the ADFR will need to remain adaptable and evolve in response to health professional feedback, changes in national metadata standards and the introduction of electronic medical records. Also, the ADFR relies on the voluntary involvement of services and with that confidential service-level data, and therefore transparency of publicly available reports is currently limited. Thus, overcoming many of these data reporting challenges relies on sufficient project funding in concert with the national digitalisation of healthcare.

There are surprisingly few international models of coordinated nationwide and comprehensive data collection on the management of DFD. The ideal data reporting system would collect and report the outcomes of entire diabetes and DFD populations to identify regional differences, such as ulcer healing, hospitalisation and amputation rates, while minimising ascertainment bias.<sup>127</sup> If differences persist after adjustment for known risk factors (e.g. age, sex, ethnicity) there may be important variations in care (e.g. access to services, adherence to quality care standards), however such in-depth analysis requires sufficient data granularity. The United Kingdom has arguably led the world in this space with the establishment of the National Health Service Digital National Diabetes Footcare Audit (NDFA) across England and Wales.<sup>128</sup> The NDFA exemplifies the power of digitalisation and government partnership,<sup>129</sup> and use of enhanced knowledge to drive quality improvement.<sup>130</sup>

In summary, the current standing of Australia's data-driven efforts to improve outcomes for people living with DFD, and at the very least the readiness of health professionals and services to conduct audits and monitor outcomes, has been demonstrated in Australia. Recent developments, including the implementation of ADFR and PROMs by services, has further proven the feasibility of national standardised data collection. The following potential areas for action for improved DFD reporting in Australia strives for equitability and excellence in diabetes footcare delivery across the country, and will see Australia further recognised internationally for innovation and leadership in this field.

## GOAL 5

**All health service regions should report their diabetes-related foot disease outcomes annually and contribute standardised data to a registry that enables benchmarking and collaboration**

### progress since inaugural strategy

- Establishment of the ADFR to report non-admitted DFD care process and clinical outcomes
- Some reporting of Australian DFD-related hospitalisation and amputation rates

### potential areas for action

- National alignment of datasets relating to DFD, with a particular focus on non-admitted care and PROMs
- Continue to integrate data collection and audit with iHRFS accreditation, and explore option of mandating minimum data contribution to the national registry (ADFR)
- Continued development of site-level reporting processes for iHRFS, including benchmarking, and prioritising use of DFD data to inform quality improvement
- Acquire funding to realise the full potential of the national registry, including access to data analytics and establishment of strategic linkages with other national datasets
- Establish national consensus standards on the definitions and codes for identifying and reporting DFD hospitalisations and amputations
- Promote and support culturally responsive First Nations-led approaches to development of datasets to address priorities of Aboriginal and Torres Strait Islander people
- Promote and support collaborative and positive use of data for priority populations for example geographically remote populations.

### potential measures of progress

- Number of national peak bodies endorsing nationally standardised DFD data collection standards, including achieving consensus on process, clinical and patient-reported outcomes across all healthcare settings
- Increased proportion of data collection capture with respect to diverse target populations
- Introduction of dedicated MBS item codes for diabetes foot screening, with requirement for data collection on risk classification, identified DFD and referring practices (with specific consideration of primary care)
- Introduction of nationally standardised PROMs for DFD to enable benchmarking
- Increased number or proportion of services that successfully integrate data collection in clinical workflows via electronic medical records
- Increased funding received towards formalising a national clinical quality registry and supporting site and national-level reporting of outcomes specifically relating to DFD

## GOAL 6

Australian national diabetes-related foot disease guidelines should continually reflect the most up-to-date evidence to guide best practice standards for healthcare provision across Australia

### Current Australian DFD guidelines

Evidence-based guidelines are the cornerstone of clinical care for all health professionals. The inaugural Australian DFD strategy recommended a key goal was the urgent updating of the previous 2011 Australian evidence-based DFD guideline.<sup>131</sup> In 2021, a suite of new Australian evidence-based DFD guidelines were developed and launched.<sup>8</sup> Prior to the development of these new Australian guidelines, DFA concluded that the substantial funding required (estimated to be >\$1 million) to develop new guidelines de novo ('from scratch') was not likely feasible to obtain for the DFD field.<sup>55</sup> Therefore, DFA decided the new 2021 Australian guidelines would be developed using the ADAPTE and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approaches; both methodological approaches recommended by the National Health and Medical Research Council (NHMRC) for adapting international guidelines to the Australian context.<sup>132</sup> An expert guidelines development group systematically identified that the 2019 International Working Group of the Diabetic Foot (IWGDF) Guidelines were the only appropriate guideline source able to be adapted as part of these approaches.<sup>133-139</sup> As such, the suite of 6 IWGDF ("International") guidelines were systemically assessed by 30 Australian multi-disciplinary clinical, research and consumer DFD experts from 7 disciplines across 6 parallel expert panels over a two year process using the ADAPTE and GRADE approaches. At the conclusion of this process, of the original 100 IWGDF guideline recommendations across the 6 guidelines, 71 recommendations were adopted, 27 adapted and two excluded for the new Australian guidelines.<sup>3,65,67,75-78</sup> This approach enabled careful and systematic considerations of the evidence in the Australian context, and included consumer and Aboriginal and Torres Strait Islander Peoples representatives input at all steps of the development. Furthermore, to maximise uptake and usability, complementary quick reference pathways, webinars, and interactive digital pathways and tools were also produced.<sup>140</sup> In total this recommended systematic process successfully adapted Australian guidelines from appropriate international source guidelines, yet involved the substantial in-kind contributions of 30 experts over a two year period.

In May 2023, an updated iteration of the IWGDF guidelines were released. This comprises 111 new or revised recommendations across the six original IWGDF guidelines comprising prevention, classification, wound healing, peripheral artery disease, infection and offloading.<sup>68,80-84,141</sup> Additionally, 26 new recommendations were also developed in a seventh IWGDF guideline, the inaugural guideline for the management of active Charcot neuro-osteoarthropathy.<sup>79</sup> Whilst at face value, the recommendations from IWGDF guidelines in 2019 and 2023 appear reasonably similar, key differences in the methodologies and recommendations exist. These include but are not limited to: 1) a systematic review (2023) instead of critical review (2019) for the classification guideline; 2) an entirely new systematic review limited to randomised controlled trials (2023) for the wound healing guideline; 3) addition of multiple new important outcomes across all guidelines following input from people with lived experience of DFD; and 4) use of a more thorough GRADE methodological approach throughout all guidelines.

### Challenges in updating national DFD guidelines

While the ADAPTE methodology offers greater efficiency compared to de novo guideline development, as outlined above the process is still resource intensive given the breadth and interdisciplinary nature of the DFD field. It was estimated the 2023 IWGDF guidelines would have cost AU\$3.2 million should the voluntary work of international experts have been reimbursed.<sup>142</sup> In comparison, the 2021 Australian guidelines engaged 30 (inter)national experts over approximately two years, with in-kind hours having an estimated value of \$100,000, in addition to the \$150,000 in grants for baseline expenses and production of implementation toolkits. A further consideration is diversion of time, which may otherwise have been invested in other projects to advance DFD care and research in Australia.



New guidelines are released every four years by the IWGDF to coincide with the International Symposium of the Diabetic Foot, the top international DFD conference. Thus, there is a risk that Australian guidelines adapted from this source may become outdated not long after their release. Whilst an obvious solution may be to simply endorse each iteration of the IWGDF guidelines soon after their release, there are benefits to having Australian guidelines. These include: 1) contextualisation to the Australian healthcare system and our vast geography; 2) involvement of Australians with lived experience of DFD; 3) involvement of and considerations with and for Aboriginal and Torres Strait Islander people; 4) greater awareness and potentially usage by primary care practitioners; and 5) endorsement by 10 national peak bodies across at least seven different medical, nursing and allied health professions significantly increasing the awareness and uptake of the guidelines. Further, other topics particularly relevant to the Australian context may be missed if guidelines are constrained to the IWGDF chapters, such as inpatient DFD management and geographical remote service delivery via telehealth.

Despite the cost, up-to-date and robust national evidence-based guidelines for DFD should always be maintained in Australia to promote best practice standards for the care of people with DFD across Australia. However, without appropriate ongoing funding for the four yearly adaptation of the new iterations of the IWGDF guidelines, reliance on in-kind work by dozens of experts over two years, is unlikely to be sustainable. An alternative to periodic adaptation may be investment in living guideline methodologies for DFD, for which the NHMRC has made arrangements,<sup>143</sup> and there is a significant precedent in Australia for diabetes guidelines in particular.<sup>144,145</sup> However, this does not negate the need for regular maintenance. Therefore, DFA, ADS and other peak national health professional bodies representing disciplines involved in DFD management across Australia have a key role in advocating for the ongoing availability of contemporary Australian evidence-based DFD guidelines, and a concerted and agreed approach to ensuring their longevity is needed.

## GOAL 6

**Australian national diabetes-related foot disease guidelines should continually reflect the most up-to-date evidence to guide best practice standards for healthcare provision across Australia**

### progress since inaugural strategy

- Launch and publication of the suite of 2021 Australian evidence-based guidelines for the prevention and management of diabetes-related foot

### potential areas for action

- Explore feasibility of Australian evidence-based DFD living guidelines, including scoping of resources required for regular maintenance
- Convene (and expand) the collaboration of the 10 peak national health professional bodies that endorsed the current Australian DFD guidelines
- Urgently develop, adapt or adopt an Australian evidence-based guideline for diagnosis and management of active Charcot neuro-osteopathy
- Evaluate clinical uptake and use of guidelines (from evidence to practice) to inform implementation success of the 2021 Australian evidence-based DFD guidelines
- Establish consumer and Aboriginal and Torres Strait Islander Peoples consultation groups to ensure all Australian DFD guideline development/maintenance are people-centric and applicable to geographical remote and Aboriginal and Torres Strait Islander Peoples
- Advocate for research funding to develop an understanding of the needs and priorities of Aboriginal and Torres Strait Islander Peoples living with DFD to inform future iterations of the guidelines

### potential measures of progress

- Development and funding of the ongoing methodology for Australian DFD living guidelines
- Launch of new iterations of Australian evidence-based DFD guidelines
- Time to launch of an inaugural Australian evidence-based active Charcot neuro-osteopathy guideline

GOAL

7

Research investment for diabetes-related foot disease should be proportional to its impact on Australians

## The disproportionality of DFD research investment with DFD impact

High quality research into diabetes and diabetes-related complications is critical to improving outcomes for all Australian people living with diabetes. However, funding investment for diabetes research in Australia is inadequate, declining by 35% over the past ten years, despite a 32% increase in the number of people living with diabetes over the same time period.<sup>146</sup> The funding shortfall for DFD research is even more critical with an enormous gap between the relatively large impact that DFD collectively causes on the Australian population and the relatively small amount of research and development funding DFD receives to address its large national impact.<sup>4,10</sup> For example, it has been reported that DFD causes around 2% of the global disease burden (or 2% of the world's health problems) yet receives <0.01% of global health research funding.<sup>4,10</sup> Such research investments shortfall for DFD is persistent around the world, having also been reported in Australia, the UK and US.<sup>4,147</sup>

Funding for health research is finite, and each individual has a reasonable claim on resources proportional to their own 'disease burden'.<sup>52</sup> However, factors like how the burden is measured, which members of the population carry the weight of the disease burden, political considerations and the impact that prior allocation (or misallocation) of funding has on the future burden of disease should also be considered.

Considering these factors, this goal strongly promotes proportionality for DFD research funding, relative to the total disease burden it causes and that of other common diseases in the Australian context. This is on the basis that firstly, DFD causes a heavy burden on the nation and globe whichever widely used metric is applied, including prevalence, incidence, disability, premature mortality, health costs and total disease burden using the formal disability-adjusted life-years (DALYs) metric.<sup>10</sup> Second, in Australia the burden of DFD is disproportionately borne by First Nations Australians and by non-Indigenous Australians living in underprivileged or remote communities,<sup>40,103</sup> further making the case for a more equitable distribution of resources. Third, the overall prevalence of diabetes, and its complications is increasing in the Australian community, and there has been limited funding for diabetes research and critically limited for DFD research over the past 10–20 years (see Figure 7).<sup>4,7,146</sup>

## Addressing the disproportionality of DFD research investment

The DFA National Strategy subcommittee has objectively quantified this mismatch in Australian research investment to disease impact for DFD compared to other conditions. This was performed by summing the research funding achieved from successful applications in recent reported years to the main (Category 1) Australian Government health research funding bodies, the NHMRC (2014–23) and Medical Research Future Fund (MRFF; 2017–23) and categorised the funding according to the primary disease or condition the application targeted or addressed.<sup>148</sup> The total amount of NHMRC research funding achieved for each disease or condition was then compared to the total global disease burden (i.e. total global DALYs) the disease or condition causes, and this is depicted in Figure 7.<sup>10,149</sup> For most conditions there is a log-linear relationship between the Australian Government health research funding successfully achieved and the total global disease burden it causes, with the obvious exception of DFD. Figure 7 demonstrates that DFD has received only ~1% of the 'proportionate' Australian government research funding it should receive relative to the total global disease burden it causes, when compared with funding allocated for cardiovascular disease, cancer, mental health, dementia, asthma, injury and arthritis and osteoporosis. DFD is also consistently underfunded relative to other diabetes complications such as diabetes-related kidney and eye disease.<sup>7,8,147</sup>

Based on this data, DFD needs at least an additional \$30–50 million per year over the next ten years from the main Australian Government health research funding bodies alone to achieve proportionality in research funding for disease burden, as per more well-known conditions with lower global burdens of disease. Even if this could be attained, it would not account for historical underfunding over the past decades, nor would it account for projected increased prevalence of diabetes and DFD complications over the next decade. Setting a clear national research agenda (Goal 8) and the establishment of a national DFD research network (Goal 9) are also important next steps that will help to improve the quality and competitiveness of DFD grant applications submitted to NHMRC, MRFF and other funding agencies in future. However, rectifying this substantial disproportionate underfunding of research for DFD is urgently required to 'level the playing field' and enable these important next steps for DFD research. Whilst a small number of successful applications for individual trials or outstanding investigators have been recently achieved, and would be welcome in the future, these will be too small in number and funding to organically address the research funding gap without a concerted rectification.



**Figure 7** Australian Government NHMRC annual research funding relative to total global disease burden for DFD compared with cardiovascular disease, cancer, mental health, dementia, asthma, injury and arthritis and osteoporosis.

**Notes:**

Conditions: Former Australian Government National Health Priorities as listed in NHMRC Research Funding statistics (<https://www.nhmrc.gov.au/funding/outcomes-and-data-research/research-funding-statistics-and-data>) and diabetes complications as listed in Global Burden of Disease Study data.<sup>10,16</sup>

Global disease burden (DALYs): Total disability-adjusted life-years (DALYs) for each condition as listed in Global Burden of Disease Study 2017 data.<sup>10,16</sup>

National funding (\$s): Mean annual national research funding achieved from NHMRC between 2014-2023 for each condition as listed in NHMRC Outcomes of funding rounds (2014 - 2023) (<https://www.nhmrc.gov.au/funding/data-research/outcomes>)

To achieve the scale required to achieve proportional research funding, a MRFF Mission should be promoted and enacted for DFD research. These large programs of work bring together key researchers, health professionals, services, industry and consumers to tackle big health challenges. A number have already been funded for common priority conditions or technologies including cardiovascular health, brain cancer, traumatic brain injury, genomics and stem cell therapies. A 'Foot Health and Disease in Diabetes Mission' would make transformative improvements in foot health in diabetes for all Australians through reducing the number of Australians of all ages affected by DFD, improving outcomes for people with DFD and improving long-term recovery and survivorship.

**GOAL**  
**7**

**Research investment for diabetes-related foot disease should be proportional to its impact on Australians**

**progress since inaugural strategy**

- Limited progress made since last strategy

**potential areas for action**

- Lobby for an Australian Government MRFF mission to tackle DFD (MRFF: Foot Health & Disease in Diabetes Mission)
- Support, endorse and promote DFD funding applications across all calls for competitive research funding via:
  - Peer review from subject matter experts
  - Providing formal endorsement from DFA
  - Leveraging research priority settings (Goal 8)
  - Applications led by national DFD Research Network (Goal 9)

**potential measures of progress**

- Announcement of a MRFF: Foot Health & Disease in Diabetes Mission or similar national DFD research program
- Increased number of successful researcher fellowships, clinical trials and cohort studies for DFD research funded via NHMRC, MRFF and other Category 1 research funding body rounds.
- Increase in proportionate research funding relative to other relevant medical conditions using rolling 10-year average

GOAL

8

An Australian foot health and disease in diabetes research framework responsive to local and national priorities should be developed

## Developing a national research framework for DFD: stakeholder engagement and priority setting

Experts and other stakeholders are well aware of many evidence gaps in the prevention and management of DFD. The purpose of developing an Australian foot health and disease in diabetes research framework is to provide a structure and focus for Australian DFD researchers and research funders to identify and address the most relevant evidence gaps that will deliver the “biggest bang for buck” for Australia DFD research whilst targeting the reduction of the large disease burden caused by DFD and being responsive to new local and national priorities

Since the inaugural strategy, progress has been made towards identifying DFD research priorities in both Australia and Europe.<sup>4,150</sup> Using a three round Delphi study open to the entire Australian DFD community, 210 stakeholders participated in a research prioritisation exercise.<sup>4</sup> Participants were mostly health professionals (58%) and consumers (34%), half of whom had lived experience of DFD. However, representation from researchers (4%) and industry (4%), including First Nations people (1%) was low.<sup>4</sup> There were striking differences between health professionals and consumers in their different research prioritisation findings. Consumers prioritised prevention, identification and management of peripheral neuropathy and peripheral artery disease as the cause of ulcers.<sup>4</sup> By contrast, health professionals prioritised management efficacy, cost-effectiveness and implementation science research for various interventions for people living with active DFD.<sup>4</sup> Findings from a similar Swedish study reinforced these DFD research prioritisation differences observed between consumer and health professional found in the Australian study.<sup>150</sup> The consumers in the Swedish study (n=51; 50%), comprised mainly those with Type 1 diabetes, of whom only 5 had a lived experience with DFD. In this group, prevention of diabetes as well as self-care, screening and education for peripheral neuropathy and peripheral artery disease were again prioritised. Like their Australian counterparts, health professionals generally prioritised management interventions for wound healing, infection and vascular insufficiency in those with active DFD.<sup>150</sup>

Rather than identifying any one research priority as being the most important, these findings emphasise that priority setting exercises are likely to be framed by the experiences of the study participants. In this context, consumers living with diabetes, but without a history of DFD will likely have had a very different journey to those with active DFD. Presumably this might also mean that their priorities are likely to be different. Similarly, priority setting among health professional stakeholders is also likely to be framed by clinical specialty and the health sector in which they work. For example, a vascular surgeon working in a tertiary hospital in a capital city is likely to have different priorities to a community podiatrist working in a remote Indigenous community. Additional limitations of the existing literature on research prioritisation for DFD is that healthcare and research funders have not been consulted in the Australian context, and almost nothing is known about priorities for First Nation Peoples, their families and Communities.<sup>4</sup>

## Key elements of an Australian foot health and disease in diabetes research framework

This goal proposes to develop a research framework that provides a structure that enables flexibility to respond to new local and national priorities as they arise. The ideal approach will acknowledge the diverse lived experiences of consumers as well as the clinical expertise of different health professionals and the needs of Australian healthcare and research funders. An Australian foot health and disease in diabetes research framework should at least cover the domains of prevention, primary care, secondary care and tertiary care. Similar approaches have been taken for other conditions important in the Australian context (e.g. Rheumatic Heart Disease).

Articulating these domains will emphasise consumer voices along the continuum of the DFD journey. Primordial prevention will acknowledge the need to understand social determinant factors which contribute to the onset of DFD, including those which underpin social and economic disadvantage. Primary care efforts for those with peripheral neuropathy and peripheral arterial disease could reflect the priorities presented by the consumers in the two research priority publications discussed above. Given the high rates of recurrence, priority setting should also focus on secondary prevention efforts. Additional efforts should be made to understand priorities amongst consumers, presenting to secondary and tertiary care with active DFD who suffer the most severe consequences of DFD such as hospitalisation, amputation and death.

Any research prioritisation exercise conducted in consumers and/or health professionals should be mapped onto the general priority and expectation needs of existing healthcare and research funders as well as align with this new Strategy and the 'evidence gaps' reported in the Australian and International DFD guidelines at the end of each guideline. Finally, in a time when access to funding to support research is limited, it is important that industry partners are given the opportunity to align their priorities within the research framework. Once the building blocks for research prioritisation are in place within each of the domains, a core set of research questions should be developed for each domain. Where there is a clear consensus on the top 3 research questions within each of the domains, possible study designs should be explored including developing consensus on study design, sample size, meaningful endpoints, and research fund applications.

For a research framework to be useful to the Australian research community, it should be widely disseminated and used to inform and strengthen applications for funding. In particular, any call for proportionate funding (Goal 7) or work within the DFD research network (Goal 9) should acknowledge and align with this DFD research framework document. In addition, to encourage uptake, from wider stakeholders, the research framework should be sent to various peak national bodies for endorsement and then published.

## GOAL 8

### **An Australian foot health and disease in diabetes research framework responsive to local and national priorities should be developed**

#### **progress since inaugural strategy**

- Initial national research priorities study of Australian DFD stakeholders published

#### **potential areas for action**

- Develop an Australian foot health and disease in diabetes research framework
- Understand Aboriginal and Torres Strait Islander people's research priorities
- Align the research framework within the DFA and IWGDF strategy and guideline documents

#### **potential measures of progress**

- An Australian foot health and disease in diabetes research framework developed
- Number of stakeholder endorsements of a published Australian foot health and disease in diabetes research framework
- Number of research priority exercises undertaken to determine domain priorities within the Australian foot health and disease in diabetes research framework
- Number and value of successfully funded projects that align with the Australian foot health and disease in diabetes research framework
- Number of future national guideline recommendations based on new Australian research that aligned with the Australian foot health and disease in diabetes research framework



GOAL

9

An Australian foot health and disease in diabetes research network should be established

## Steps towards an Australian foot health and disease in diabetes research network

A thriving and sustainable Australian DFD research community is central to achieving improved outcomes for people living with DFD and a reduction in the large national disease burden caused by DFD. A recent bibliometric study of Australian DFD research outputs and funding sources from 1970 to 2023 revealed that although there was a steady increase in publications, most Australian DFD published research received no dedicated funding and predominantly investigated aetiology, existing treatments and health service delivery.<sup>13</sup> There was a dearth of well-resourced clinical trials, research with and for First Nations Peoples and studies into DFD prevention.<sup>13</sup> Thus, the Australian DFD research community appears to be a productive and resilient community considering this large recent increase in publications despite minimal funding. However, to conduct research that has potential to greatly improve the lives of people living with, or at risk of DFD, a marked increase in funding, research training and research activity will be required across Australia.

An Australian foot health and disease in diabetes research network needs to be established, to attract Australian and international investigator-initiated and industry-initiated research projects and funding. Such a network's objectives and activities should be based on developed national research priorities (Goal 8). The research network could encourage and coordinate active involvement with all interested key consumer, health professional, researcher and industry stakeholder groups. With demonstration that a research network has the capacity and skills to undertake high impact and culturally responsive research, large research funding bids that bridge the enormous gap between the impact of DFD and the research investment in DFD are also more likely to be successful (Goal 7).

In October 2023, a meeting of stakeholders and interested parties was held prior to the 2023 DFA National DFD conference to introduce the idea of a DFD focused research network to the Australian community of DFD researchers and health professionals. The aim of the meeting was to commence discussion on a national approach to DFD research in Australia, to collaboratively introduce concepts of research organisational models,<sup>151</sup> funding structures and professional networks, and as well as to gauge the level of support for a DFD focused research network from the Australian DFD research and health professional community. Stakeholders shared a vision of a DFA research network that valued excellence, collaboration, inclusion, listening to community, partnering with consumers, innovation, and empowerment. Nearly 90% of respondents were interested in participating in a future Australian DFD research network workshop. Therefore, DFA is intending to undertake further such national research network development activities to progress the development of an Australian foot health and disease in diabetes research network.

The important first steps in progressing towards an Australian research network must be focused on building research skills, knowledge and capacity, and fostering greater collaboration across Australia and internationally. The DFD research community should have the skills and knowledge to engage in high quality, rigorous, appropriately powered and resourced, multisite observational studies and clinical trials. There should be the capacity to support implementation of First Nations-led research that addresses self-determined needs and priorities of First Nations Communities. Therefore, the early activities of the research network must focus on development, education, training and building a diverse research community that can collaborate and engage effectively. It is also critical that there is a strong future focus on engagement and collaboration with people living with diabetes and DFD, those living in rural and remote areas, health professionals involved in DFD management outside of iHRFS, and First Nations Communities to support research that is informed by lived experience and that addresses the needs and priorities of populations who are disproportionately affected by DFD.

There is also an urgent need to decolonise research in Australia and for DFD research to be undertaken with and for First Nations Peoples to inform clinical guidelines and care.<sup>103,152,153</sup> Self-determined First Nations-led co-designed DFD research underpinned by Indigenous methodologies that challenge the worldviews that have historically informed use of unethical research methods and discriminatory research designs is essential to engaging First Nations Communities and identifying their national priorities for First Nations DFD research.<sup>1,154,155</sup> This includes engagement with and empowerment of First Nations organisations, including health services providers and peak bodies, First Nations Communities and researchers to value and promote Indigenous research methodologies and research outcomes and support development of robust processes, Indigenous data governance and sovereignty. A national research network simultaneously investing in high quality mainstream academic research through RCTs, First Nations-led research privileging Indigenous methodologies, and research integrating these knowledge systems will potentially create the greatest benefits and quickest national and global impact.

## Next generation researchers

A research network also provides unique opportunities to nurture the next generation of DFD researchers. The best opportunity for early career researchers is to be made part of large, high-quality, studies. Ideally, when setting up studies, roles should be created for early career researchers to do the ‘footwork’ in these studies. Furthermore, DFD research should be supportive of increasing capacity of First Nations researchers and First Nations health organisations to undertake DFD research with Aboriginal and Torres Strait Islander Communities. Additionally, it is critical to provide support to DFD discovery science researchers and PhD students, building capacity and sustainability in this important research area. DFD researchers and universities considering DFD research should be encouraged to align PhD student’s topics with national DFD research priorities (goal 8) and research network activities once established. A culturally responsive mentoring system should be created for researchers and preferably within the research network. To further stimulate the next generation of DFD researchers, a “National DFD Early Career Researcher Award” should be created. This should be promoted and awarded at a DFA National DFD Conference and may provide the recipient with (for example) dedicated mentoring-support for two years, a small travel grant to visit international researchers and related forums, and an allocated keynote presentation at the next national conference to present their findings.

## Research skills development and training

Research on DFD has many intricacies that are specific to the multi-disciplinary nature of the DFD field, and it requires education and training to understand and appreciate these intricacies.<sup>156,157</sup> Training modules should be developed, aiming to improve the knowledge and skills for novice and early career researchers in the field of DFD research. Training modules should also be provided to increase knowledge and understanding of Indigenous methodologies and working with First Nations Communities to support self-determined research and culturally responsive research practice. Module content may also include critical assessment of the history and salient DFD publications; designing research studies; data capture and analysis and minimum reporting standards.<sup>156,157</sup>

## Cooperation

Finally, this goal is a call to all Australian DFD researchers, health professionals and consumers to maximise communication, cooperation and collaboration around multi-centre studies and funding application plans. Furthermore, it is incumbent upon all non-Indigenous DFD researchers to give up space for First Nations-led research, and emerging and established First Nations researcher leaders, and develop knowledge and capabilities to promote wider understanding and acknowledgement of the central and valuable role of Indigenous research methodologies and research outcomes for addressing DFD. Research is a highly competitive world and, by its history and its nature, rather hierarchical. Like DFD clinical services, interdisciplinary cooperation rather than competition is the primary strategy for long-term success to improve the clinical and research outcomes of people with DFD and in turn reduce the comparatively high national disease burden caused by DFD.

## GOAL 9

**An Australian foot health and disease in diabetes research network should be established**

### progress since inaugural strategy

- Australian DFD Research Network stakeholder engagement activities commenced

### potential areas for action

- Establish an Australian foot health and disease research network
- Initiate research programs including RCTs, observational studies and discovery science within the research network that align with national research priorities (Goal 8)
- Support First Nations-led research programs within the research network
- Promote results from Australian DFD research to health professionals, consumers, communities, industry and funding bodies
- Establish a "National DFD Early Career Researcher Award", including a specific award for First Nations researchers
- Establish DFD research training modules for novice researchers

### potential measures of progress

- Increased number and amount of funding provided to DFD studies and projects within the Australian DFD Research Network and Australian institutions, including specific funding for First Nations-led research projects
- Increased number of researchers and PhD students undertaking DFD research that aligns with national research priorities
- Number of accredited iHRFS participating in the research network
- Number of consumers participating in research within the research network
- Number of publications, theses and conference presentations resulting from the research network and Australian institutions
- Increased proportion of funds for DFD research projects from the total national health and diabetes research funding available

## ABBREVIATIONS

ADS	Australian Diabetes Society
ADFR	Australian Diabetes Foot Registry
APP-HRF	Advanced Practicing Podiatrists – High Risk Foot Group
DALY	Disability Adjusted Life Years
DFA	Diabetes Feet Australia
DFD	Diabetes-related Foot Disease
DFU	Diabetes-related Foot Ulcer
DVA	Department of Veteran Affairs
FTE	Full Time Equivalent
GRADE	Grading of Recommendations, Assessment, Development and Evaluation
iHRFS	Interdisciplinary high risk foot services
IWGDF	International Working Group on the Diabetic Foot
MBS	Medicare Benefits Schedule
MRFF	Medical Research Future Fund
NADC	National Association of Diabetes Centres
NDFA	National Diabetes Footcare Audit
NDSS	National Diabetes Services Scheme
NDIS	National Disability Insurance Scheme
NHMRC	National Health and Medical Research Council
OECD	Organisation of Economic Co-operation and Development
PAD	Peripheral Artery Disease
PBS	Pharmaceutical Benefits Scheme
PHI	Private health insurance
PROMS	Patient-reported outcome measures
QHRFF	Queensland High Risk Foot Form
RCT	Randomised Control Trial
SAHMRI	South Australian Health & Medical Research Institute

### Appendix 1: Health professional disciplines who may be involved in the care of a person with DFD

The list below provides an indication of the types of health professional disciplines that may be part of the health workforce working with people with diabetes to maintain or improve their foot health. The list is in alphabetical order, likely incomplete, with certain circumstances potentially requiring input from other disciplines not listed as well.<sup>49,108</sup>

#### Disciplines

Aboriginal and Torres Strait Islander Health Practitioner

Allied Health Assistant / Assistant in Nursing

Cardiologist

Chronic Pain Specialist

Credentialed Diabetes Educator

Dermatologist

Diabetes Nurse Practitioner

Endocrinologist/Diabetologist/Physician

Exercise Physiologist

Family/carers

General Practitioner

Geriatrician

Infectious Diseases Specialist

Nephrologist

Neurologist

Orthopaedic Surgeon

Orthotist and/or Pedorthist

Other support services (e.g. NDSS information and support service)

Physiotherapist

Plastic Surgeon

Podiatric Surgeon

Podiatrist

Psychiatrist

Psychologist

Radiologist

Rehabilitation Specialist

Social worker/Counsellor

Vascular Surgeon

Wound Care Nurse



**Table 1** Estimated burden caused by DFD on Australia and per 100,000 residents each year

Characteristic	Australia <sup>a</sup>	Per 100,000 <sup>b</sup>
<b>Populations</b>		
People with diabetes <sup>c</sup>	1,500,000	5,556
People with DFD <sup>d</sup>	510,000	1,889
People with active DFD <sup>e</sup>	51,000	189
People with diabetes-related amputations <sup>f</sup>	25,000	94
<b>Hospitalisations</b>		
People in a hospital bed because of DFD <sup>g</sup>	471,000	1,744
Public Hospital	376,500	1,394
Private Hospital	94,500	350
People newly admitted to hospital because of DFD <sup>h</sup>	47,100	174
Public Hospital	37,650	139
Private Hospital	9,450	35
<b>Amputations</b>		
People undergoing an amputation because of DFD <sup>i</sup>	6,300	23.3
Public Hospital	5,250	19.4
Private Hospital	1,050	3.9
People undergoing a minor amputation because of DFD <sup>j</sup>	5,250	19.4
Public Hospital	4,350	16.1
Private Hospital	900	3.3
People undergoing a major amputation because of DFD <sup>k</sup>	1,050	3.9
Public Hospital	900	3.3
Private Hospital	150	0.6
<b>Mortality</b>		
Deaths from DFD <sup>l</sup>	2,500	9.3
<b>Costs</b>		
Total direct costs because of DFD <sup>m</sup>	\$2.69 Billion	\$9.96 Million
Hospital costs because of DFD <sup>n</sup>	\$1.09 Billion	\$4.04 Million
Primary care and other recurrent health costs because of DFD <sup>o</sup>	\$1.60 Billion	\$5.92 Million

DFD = Diabetes-related foot disease; <sup>a</sup> Estimated burden for the 27,000,000 resident population of Australia in 2024<sup>158</sup>; <sup>b</sup> Estimated burden for every 100,000 resident population of Australia in 2024 (i.e. 100,000 / 27,000,000); <sup>c</sup> Number of Australians with diagnosed diabetes in 2023<sup>25</sup>; <sup>d</sup> Prevalence with DFD (~34%)<sup>11,29</sup> x number of Australians with diagnosed diabetes in 2023<sup>25</sup>; <sup>e</sup> Prevalence of those with active DFD (~3.4%: 3.2% ulcer (+/-infection)<sup>10,11,29</sup> + 0.1% active Charcot neuro-osteopathy<sup>10,79</sup> + 0.1% gangrene<sup>36,79,82,159</sup>) x number of Australians with diagnosed diabetes in 2023<sup>25</sup>; <sup>f</sup> Prevalence of those with a previous diabetes-related amputation (~1.7%)<sup>11,29</sup> x number of Australians with diagnosed diabetes in 2023<sup>25</sup>; <sup>g</sup> Incidence of overnight hospital admissions per year for DFD (31.4 per 1,000 person-years with diabetes, i.e. 25.1 public hospital admissions + 6.3 private hospital admissions)<sup>26</sup> x number of per 1,000 Australians with diagnosed diabetes in 2023 (i.e. 1,500,000 / 1,000)<sup>25</sup> x 10 day median length of hospital stay for a DFD hospital admission<sup>18,31,85</sup>; <sup>h</sup> Incidence of overnight hospital admissions per year for DFD (31.4 per 1,000 person-years with diabetes)<sup>26</sup> x number of Australians with diagnosed diabetes in 2023<sup>25</sup>; <sup>i</sup> Incidence of overnight hospital admissions per year for diabetes-related amputation (4.2 per 1,000 person-years with diabetes)<sup>18,24,26</sup> x number of Australians with diagnosed diabetes in 2023<sup>25</sup> (including 3.5 for minor amputations<sup>j</sup> and 0.7 major amputations<sup>k</sup> per 1,000 person-years with diabetes)<sup>18,24,26</sup>; <sup>j</sup> Incidence of overnight hospital admissions per year for minor diabetes-related amputation (i.e. 3.5 per 1,000 person-years with diabetes, i.e. 2.9 public hospital admissions + 0.6 private hospital admissions)<sup>18,24,26</sup> x number of Australians with diagnosed diabetes in 2023<sup>25</sup>; <sup>k</sup> Incidence of overnight hospital admissions per year for major diabetes-related amputation (i.e. 0.7 per 1,000 person-years with diabetes, i.e. 0.6 public hospital admissions + 0.1 private hospital admissions)<sup>18,24,26</sup> x number of Australians with diagnosed diabetes in 2023<sup>25</sup>; <sup>l</sup> Incidence of excess all-cause deaths in people with active DFD compared to those with diabetes without active DFD (49.3 excess all-cause deaths per 1,000 person-years with diabetes)<sup>21</sup> x number of Australians with active DFD<sup>e</sup> (51,000 / 1,000); <sup>m</sup> Total direct healthcare costs incurred by DFD to the Australian Health System in 2023 (\$AU2.69 billion = \$1.09 billion in hospital costs<sup>n</sup> x 2.51 for primary care and other recurrent health costs, i.e. total health care costs = 40% hospital costs + 60% primary care and other recurrent costs)<sup>22</sup>; <sup>n</sup> Total hospital costs (\$AU1.09 billion in 2023, i.e. \$939 million in 2020 = (\$729 million hospitalisation costs = \$15,477 per Australian hospitalisation for DFD<sup>23,27</sup> x 47,100 hospitalisations per year) + (\$160.3 million minor amputation costs = \$30,530 per Australian minor amputation<sup>23,27</sup> x 5,250 minor amputations) + (\$49.7 million major amputation costs = \$47,327 per Australian major amputation<sup>23,27</sup> x 1,050 major amputations)); <sup>o</sup> Total primary care and other recurrent health costs make up 60% of total direct healthcare costs in Australia (i.e. \$AU1.60 billion in 2023).<sup>22</sup>

**Table 2** Forecasted savings if guideline-based care for people living with DFD is systematically implemented across Australia and per 100,000 Australian residents each year

Characteristic	Australia <sup>a</sup>	Per 100,000 <sup>b</sup>
<b>Morbidity savings</b>		
People prevented from being in a hospital bed <sup>c</sup>	188,400	698
People prevented from being admitted to hospital <sup>d</sup>	20,250	75
People prevented from undergoing an amputation <sup>e</sup>	2,840	10.5
<b>Mortality savings</b>		
People prevented from dying <sup>f</sup>	1,125	4.2
<b>Cost savings</b>		
Costs prevented to health system <sup>g</sup>	\$0.94 Billion	\$3.48 Million

DFD = Diabetes-related foot disease; <sup>a</sup> Estimated savings for the 27,000,000 resident population of Australia in 2024<sup>158</sup>; <sup>b</sup> Estimated savings for every 100,000 resident population of Australia in 2017 (i.e. 100,000 / 27,000,000); <sup>c</sup> People in a hospital bed because of DFD in Table 1 x percentage reduction demonstrated in people in a hospital bed because of DFD after systematic implementation of evidence-based care (~40%)<sup>85</sup>; <sup>d</sup> People newly admitted to hospital overnight because of DFD in Table 1 x percentage reduction demonstrated in people newly admitted to hospital overnight because of DFD after systematic implementation of evidence-based care (~43%)<sup>85</sup>; <sup>e</sup> People undergoing a diabetes-related amputation in Table 1 x percentage reduction demonstrated in people undergoing diabetes-related amputations after systematic implementation of evidence-based care (~45%)<sup>85,160,161</sup>; <sup>f</sup> People dying from DFD in Table 1 x percentage reduction demonstrated in people dying from DFD after systematic implementation of evidence-based care (~45%)<sup>21,162</sup>; <sup>g</sup> Estimated costs to all health systems from DFD in Table 1 x percentage reduction demonstrated in estimated costs to all health systems from DFD after systematic implementation of evidence-based care (~35%)<sup>27,43-45</sup>; <sup>h</sup> Estimated costs to hospitals from DFD in Table 1 x percentage reduction demonstrated in estimated costs to hospitals from DFD after systematic implementation of evidence-based care (~35%)<sup>27,43,45</sup>.

**Table 3** Estimated full-time equivalent health professional and interdisciplinary high risk foot services (iHRFS) required to ensure access to systematic evidence-based care for people with, or at-risk of, diabetes-related foot ulcers across Australia each year

Characteristic	Australia <sup>a</sup>	Per 100,000 <sup>b</sup>
<b>LEVEL 1 CARE Screening for all people living with diabetes</b>		
People with diagnosed diabetes <sup>c</sup>	1,500,000	5,556
Number of health professional consultations required to perform screening <sup>d</sup>	1,500,000	5,556
Number of FTE health professionals required to perform screening <sup>e</sup>	313	1.2
<b>LEVEL 2 CARE Prevention of all people at-risk of DFU</b>		
People at-risk of DFU <sup>f</sup>	510,000	1,899
Number of health professional consultations required to perform prevention <sup>g</sup>	2,040,000	7,556
Number of FTE health professionals required to perform prevention <sup>h</sup>	425	1.6
<b>LEVEL 3a CARE Care for all people with active DFD (inc DFU) in ambulatory settings</b>		
People living with active DFD <sup>i</sup>	51,000	289
Number of iHRFS consultations required to perform ambulatory care <sup>j</sup>	2,650,000	9,815
Number of FTE iHRFS required to perform ambulatory care <sup>k</sup>	550	2.0
<b>LEVEL 3i CARE Care for all people with active DFD (inc DFU) in inpatient hospital settings</b>		
People in a hospital bed because of DFD <sup>l</sup>	471,000	1,744
Number of iHRFS consultations required to perform inpatient care <sup>m</sup>	471,000	1,744
Number of iHRFS required to perform inpatient care <sup>n</sup>	64.5	0.2

DFD = Diabetes-related foot disease; DFU = diabetes-related foot ulcer; FTE = full-time equivalent; iHRFS = interdisciplinary high risk foot services. <sup>a</sup> Estimated population needing care and workforce required to adequately care for that population using the 27,000,000 resident population of Australia in 2024 <sup>158</sup>; <sup>b</sup> Estimated population needing care and workforce required to adequately care for that population for every 100,000 resident population of Australia in 2024 (i.e. 100,000 / 27,000,000); <sup>c</sup> Number of Australians with diagnosed diabetes in 2023 <sup>25</sup>; <sup>d</sup> Number of people living with diabetes x number of consultations required to adequately perform foot screening per year for each person (one screening consultation per year is required <sup>55</sup>); <sup>e</sup> Number of consultations required to adequately perform DFU screening per year / 4,800 x foot screening consultations able to be performed by one full time equivalent (FTE) health professional performing a DFU screening role only (20 x DFU screening consultations per day (assumed one screening takes 20 minutes) x 240 available working days per year); <sup>f</sup> Prevalence of those at-risk of DFU (~34%) <sup>11,29</sup> x number of Australians with diagnosed diabetes in 2023 <sup>25</sup>; <sup>g</sup> Number of people at-risk of DFU x average number of consultations required to adequately perform DFU prevention per year for each person (average of 4 consultations per year assumed as numbers of consultations required range from 2 per year for those at low risk to 12 per year for those at high risk of DFU <sup>55</sup>); <sup>h</sup> Number of consultations required to adequately perform DFD prevention per year / 4,800 x foot prevention consultations able to be performed by one FTE health professional performing a DFU prevention role only (20 x DFU prevention consultations per day (assumed one prevention consultation takes 20 minutes) x 240 available working days per year); <sup>i</sup> Prevalence of those with active DFD (~3.4%: 3.2% ulcer (+/-infection) <sup>10,11,29</sup> + 0.1% active Charcot neuro-osteoarthropathy <sup>10,79</sup> + 0.1% gangrene <sup>36,84,163</sup>) x number of Australians with diagnosed diabetes in 2023 <sup>25</sup>; <sup>j</sup> Number of people with active DFD x number of iHRFS consultations required to adequately perform active DFD care per year for each person (average of 52 iHRFS consultations assumed as a person with DFD requires weekly care <sup>55</sup>); <sup>k</sup> Number of iHRFS consultations required to adequately perform active DFD care per year / 4,800 x iHRFS care consultations able to be performed by one FTE iHRFS (involving 2+ health professionals) performing an active DFD care role only (20 x DFD care consultations per day (assumed one care consultation takes 20 minutes) x 240 available working days per year); <sup>l</sup> Incidence of overnight hospital admissions per year for DFD (31.4 per 1,000 person-years with diabetes) <sup>26</sup> x number of Australians with diagnosed diabetes in 2023 <sup>25</sup> x 10 day median length of hospital stay for a DFD hospital admission <sup>18,31,85</sup>; <sup>m</sup> Number of inpatients in hospital each day for DFD x number of iHRFS consultations required to adequately perform DFD care for each inpatient (average of one iHRFS consultations assumed as an inpatient with DFD requires daily review <sup>163</sup>); <sup>n</sup> Number of iHRFS consultations required to adequately perform DFD care per year / 7,300 x iHRFS care consultations able to be performed by one FTE iHRFS (involving 2+ health professionals) performing a DFD care role only (20 x DFD care consultations per day (assumed one care consultation takes 20 minutes) x 365 available working days per year).

## REFERENCES

1. Bodkin-Andrews G, Carlson B. The legacy of racism and Indigenous Australian identity within education. *Race Ethnicity and Education* 2016; 19(4): 784–807.
2. Purdie N, Dudgeon P, Walker R. Working together: Aboriginal and Torres Strait Islander mental health and wellbeing principles and practice. 1st ed. Canberra: Commonwealth of Australia; 2010.
3. Lazzarini PA, Raspovic A, Prentice J, et al. Guidelines development protocol and findings: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. *Journal of Foot and Ankle Research* 2022; 15(1): 28.
4. Perrin BM, Raspovic A, Williams CM, et al. Establishing the national top 10 priority research questions to improve diabetes-related foot health and disease: a Delphi study of Australian stakeholders. *BMJ Open Diabetes Research & Care* 2021; 9(2): e002570.
5. van Netten JJ, Lazzarini PA, Armstrong DG, et al. Diabetic Foot Australia guideline on footwear for people with diabetes. *Journal of Foot and Ankle Research* 2018; 11(1): 2.
6. Diabetic Foot Australia. Australian Diabetic Foot Ulcer Minimum Dataset Dictionary Version 1.0. Brisbane: DFA; 2016. [https://www.diabetesfeetaustralia.org/wp-content/uploads/Australian-Diabetic-Foot-Ulcer-Minimum-Dataset-Dictionary-published\\_v1.0\\_.pdf](https://www.diabetesfeetaustralia.org/wp-content/uploads/Australian-Diabetic-Foot-Ulcer-Minimum-Dataset-Dictionary-published_v1.0_.pdf) (accessed 11 June 2025).
7. Lazzarini PA, van Netten JJ, Fitridge RA, et al. Pathway to ending avoidable diabetes-related amputations in Australia. *Medical Journal of Australia* 2018; 209(7): 288–90.
8. van Netten JJ, Lazzarini PA, Fitridge R, et al. Australian diabetes-related foot disease strategy 2018–2022: The first step towards ending avoidable amputations within a generation. Brisbane: Diabetic Foot Australia, Wound Management CRC; 2017. [https://www.diabetesfeetaustralia.org/wp-content/uploads/2020/12/Australian-diabetes-related-foot-disease-strategy-2018-2022-DFA2020.pdf?\\_gl=1\\*v3rc45\\*\\_ga\\*MTg5NzU2NzUxLjE2ODE5NDg2Njg.\\*\\_up\\*MQ](https://www.diabetesfeetaustralia.org/wp-content/uploads/2020/12/Australian-diabetes-related-foot-disease-strategy-2018-2022-DFA2020.pdf?_gl=1*v3rc45*_ga*MTg5NzU2NzUxLjE2ODE5NDg2Njg.*_up*MQ) (accessed 11 June 2025).
9. van Netten JJ, Bus SA, Apelqvist J, et al. Definitions and criteria for diabetes-related foot disease (IWGDF 2023 update). *Diabetes Metab Res Rev* 2024; 40(3): e3654.
10. Lazzarini PA, Raspovic KM, Meloni M, Van Netten JJ. A new declaration for feet's sake: Halving the global diabetic foot disease burden from 2% to 1% with next generation care. *Diabetes/Metabolism Research and Reviews* 2024; e3747.
11. Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global disability burdens of diabetes-Related lower-extremity complications in 1990 and 2016. *Diabetes Care* 2020; 43(5): 964–74.
12. Australian Diabetes Society. About the Australian Diabetes Society. 2024. <https://www.diabetessociety.com.au/about-the-australian-diabetes-society/> (accessed 26th October 2024).
13. Tehan PE, Perrin BM, Lazzarini PA, Al-Busaidi IS, Carroll MR. How far has diabetes-related foot disease research progressed in Australia: a bibliometric analysis (1970–2022). *Journal of Foot and Ankle Research* 2023; 17(2): e12012.
14. Health Practitioner Regulation National Law Act 2009. State of Queensland.
15. Australian Health practitioner Regulation Agency. Joint statement: Aboriginal and Torres Strait Islander health and cultural safety at heart of National Law changes. 2022. <https://www.ahpra.gov.au/About-Ahpra/Ministerial-Directives-and-Communiqués/National-Law-amendments/Joint-statement.aspx> (accessed 29th October 2024).
16. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* 2020; 396(10258): 1204–22.
17. Lazzarini PA, Pacella RE, Armstrong DG, Van Netten JJ. Diabetes-related lower-extremity complications are a leading cause of the global burden of disability. *Diabetic Medicine* 2018; 35: 1297–9.
18. Lazzarini PA, Cramb SM, Gollidge J, Morton JI, Magliano DJ, Van Netten JJ. Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. *Diabetologia* 2023; 66(2): 267–87.
19. Wukich DK, Raspovic KM. Assessing health-related quality of life in patients with diabetic foot disease: why is it important and how can we improve? The 2017 Roger E. Pecoraro award lecture. *Diabetes Care* 2018; 41(3): 391–7.
20. Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. *Journal of Foot and Ankle Research* 2020; 13(1): 16.
21. Saluja S, Anderson SG, Hambleton I, et al. Foot ulceration and its association with mortality in diabetes mellitus: a meta-analysis. *Diabetic Medicine* 2020; 37(2): 211–8.
22. Australian Institute of Health Welfare. Health expenditure Australia 2021–22. Canberra: AIHW, 2023. <https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2021-22/contents/about> (accessed 11 June 2025).
23. Independent Hospital Pricing Authority. National efficient price determination 2020–21. In: Independent Hospital Pricing Authority, editor; 2020. <https://www.ihacpa.gov.au/resources/national-efficient-price-determination-2020-21> (accessed 11 June 2025).
24. Morton JI, Lazzarini PA, Shaw JE, Magliano DJ. Trends in the incidence of hospitalization for major diabetes-related complications in people with type 1 and type 2 diabetes in Australia, 2010–2019. *Diabetes Care* 2022; 45(4): 789–97.
25. National Diabetes Services Scheme. Australian diabetes map. 2023. <https://www.ndss.com.au/about-diabetes/diabetes-facts-and-figures/australian-diabetes-map/> (accessed 2nd April 2023).
26. Quigley M, Morton JI, Lazzarini PA, Zoungas S, Shaw JE, Magliano DJ. Trends in diabetes-related foot disease hospitalizations and amputations in Australia, 2010 to 2019. *Diabetes Research and Clinical Practice* 2022; 194: 110189.
27. Zhang Y, Carter HE, Lazzarini PA, et al. Cost-effectiveness of guideline-based care provision for patients with diabetes-related foot ulcers: A modelled analysis using discrete event simulation. *Diabetic Medicine* 2023; 40(1): e14961.

## REFERENCES

28. Byrnes JM, Ward L, Jensen S, et al. Health-related quality of life in people with different diabetes-related foot ulcer health states: a cross-sectional study of healed, non-infected, infected, hospitalised and amputated ulcer states. *Diabetes Res Clin Pract* 2024; 207: 111061.
29. Zhang Y, van Netten JJ, Baba M, et al. Diabetes-related foot disease in Australia: a systematic review of the prevalence and incidence of risk factors, disease and amputation in Australian populations. *Journal of Foot and Ankle Research* 2021; 14(1): 8.
30. Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. health-related quality of Life in patients with different diseases measured with the EQ-5D-5L: A systematic review. *Frontiers in Public Health* 2021; 9(802): 675523.
31. Zhang Y, Cramb SM, McPhail SM, Pacella RE, Van Netten JJ, Kinnear EM, et al. The incidence of and risk factors for hospitalisations and amputations for people with diabetes-related foot ulcers in Queensland, 2011-19: an observational cohort study. *The Medical Journal Of Australia*. 2025; Accepted 6th January 2025.
32. Squires DA. The U.S. health system in perspective: a comparison of twelve industrialized nations. *Issue Brief (Commonw Fund)* 2011; 16: 1-14.
33. Bureau of Health Information. Healthcare in focus: how NSW compares internationally. Sydney: NSW Government, 2010. [https://www.bhi.nsw.gov.au/BHI\\_reports/healthcare\\_in\\_focus/2010](https://www.bhi.nsw.gov.au/BHI_reports/healthcare_in_focus/2010) (accessed 11 June 2025)
34. Lazzarini PA, Gurr JM, Rogers JR, Schox A, Bergin SM. Diabetes foot disease: the Cinderella of Australian diabetes management? *Journal of Foot and Ankle Research* 2012; 5(1): 24.
35. Australian Institute of Health & Welfare (AIHW). OECD health care quality and outcomes indicators, Australia 2022-23. Canberra, Australia: Australian Institute of Health & Welfare (AIHW), 2024. <https://www.aihw.gov.au/reports/international-comparisons/oecd-health-care-indicators-2022-23/contents/about> (accessed 11 June 2025).
36. Organisation for Economic Co-operation and Development. Health at a Glance 2023: OECD Indicators. Paris: OECD Publishing; 2023. [https://www.oecd.org/en/publications/2023/11/health-at-a-glance-2023\\_e04f8239.html](https://www.oecd.org/en/publications/2023/11/health-at-a-glance-2023_e04f8239.html) (accessed 11 June 2025).
37. Carinci F, Uccioli L, Massi Benedetti M, Klazinga NS. An in-depth assessment of diabetes-related lower extremity amputation rates 2000-2013 delivered by twenty-one countries for the data collection 2015 of the Organization for Economic Cooperation and Development (OECD). *Acta Diabetologica* 2020; 57(3): 347-57.
38. Alahakoon C, Thanigaimani S, Singh TP, et al. Association of remoteness and ethnicity with major amputation following minor amputation to treat diabetes-related foot disease. *PLoS ONE* 2024; 19(7): e0302186.
39. Singh TP, Moxon JV, Meehan MT, Jones R, Cadet-James Y, Gollidge J. Major amputation rates and outcomes for Aboriginal and Torres Strait Islander and non-Indigenous people in North Queensland Australia between 2000 and 2015. *BMC Endocrine Disorders* 2021; 21(1): 101.
40. West M, Chuter V, Munteanu S, Hawke F. Defining the gap: a systematic review of the difference in rates of diabetes-related foot complications in Aboriginal and Torres Strait Islander Australians and non-Indigenous Australians. *Journal of Foot and Ankle Research* 2017; 10(1): 48.
41. Hamilton EJ, Davis WA, Siru R, Baba M, Norman PE, Davis TME. Temporal trends in incident hospitalization for diabetes-related foot ulcer in Type 2 diabetes: The Fremantle diabetes study. *Diabetes Care* 2021; 44(3): 722-30.
42. Morton JI, Lazzarini PA, Polkinghorne KR, Carstensen B, Magliano DJ, Shaw JE. The association of attained age, age at diagnosis, and duration of type 2 diabetes with the long-term risk for major diabetes-related complications. *Diabetes Research and Clinical Practice* 2022; 190: 110022.
43. Cheng Q, Lazzarini PA, Gibb M, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. *International Wound Journal* 2017; 14(4): 616-28.
44. Frescos N, Stopher L, Jansen S, Kaminski MR. The financial burden of diabetes-related foot disease in Australia: a systematic review. *Journal of Foot and Ankle Research* 2023; 16(1): 92.
45. Griffith University Centre for Applied Health Economics. An economic evaluation of a novel funding model for diabetic foot disease: Findings report. Brisbane: Queensland Government, Brisbane, Australia; 2022.
46. World Health Organisation. Health equity. 2024. [https://www.who.int/health-topics/health-equity#tab=tab\\_1](https://www.who.int/health-topics/health-equity#tab=tab_1) (accessed 26th October 2024).
47. Chuter V, Charles J, Fitridge R. Delivering equitable access to diabetes foot care services. *European Journal of Vascular and Endovascular Surgery* 2024; 68(1): 3-5.
48. Tehan PE, Hawes MB, Hurst J, Sebastian M, Peterson BJ, Chuter VH. Factors influencing lower extremity amputation outcomes in people with active foot ulceration in regional Australia: A retrospective cohort study. *Wound Repair Regen* 2022; 30(1): 24-33.
49. van Netten JJ, Apelqvist J, Bus SA, et al. The unique multidisciplinary of diabetes-related foot disease. *Diabetes/ Metabolism Research and Reviews* 2024; 40(4): e3804.
50. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *BMJ* 1996; 312(7023): 71-2.
51. National Institute for Health and Care Excellence: Guidelines. Advocacy services for adults with health and social care needs. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2022.; 2022. <https://www.nice.org.uk/guidance/ng227> (accessed 11 June 2025).
52. Millum J. Should health research funding be proportional to the burden of disease? *Politics, Philosophy & Economics* 2022; 22(1): 76-99.
53. Indigenous Allied Health Australia. Aboriginal and Torres Strait Islander diabetes related foot complications program- development of a workforce model. Canberra, 2022.
54. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. *New England Journal of Medicine* 2017; 376(24): 2367-75.



## REFERENCES

55. Lazzarini PA, Raspovic A, Prentice J, et al. Australian evidence-based guidelines for the prevention and management of diabetes-related foot disease: a guideline summary. *Medical Journal of Australia* 2023; 219(10): 485–95.
56. Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). *Diabetes/Metabolism Research and Reviews* 2024; 40(3): e3657.
57. Australian Institute of Health and Welfare. Diabetes: Australian facts. 2024. <https://www.aihw.gov.au/reports/diabetes/diabetes/contents/about> (accessed 11 June 2025).
58. Monash University School of Public Health and Preventive Medicine. Australian Diabetes Clinical Quality Registry Annual Report 2023, 2024. <https://www.monash.edu/medicine/sphpm/registries/adqcr>
59. Tapp RJ, Zimmet PZ, Harper CA, et al. Diabetes care in an Australian population: frequency of screening examinations for eye and foot complications of diabetes. *Diabetes Care* 2004; 27(3): 688–93.
60. Tehan PE, Chuter VH. Vascular assessment techniques of podiatrists in Australia and New Zealand: a web-based survey. *Journal of Foot and Ankle Research* 2015; 8: 1–8.
61. Leese GP, Stang D. When and how to audit a diabetic foot service. *Diabetes/Metabolism Research and Reviews* 2016; 32: 311–7.
62. Ademi Z, Liew D, Chew D, et al. Drug treatment and cost of cardiovascular disease in Australia. *Cardiovascular therapeutics* 2009; 27(3): 164–72.
63. Mengistu TS, Khatri R, Erku D, Assefa Y. Successes and challenges of primary health care in Australia: A scoping review and comparative analysis. *Journal of Global Health* 2023; 13: 04043.
64. Butler T, Gall A, Garvey G, et al. A Comprehensive Review of Optimal Approaches to Co-Design in Health with First Nations Australians. *International Journal of Environment Research and Public Health* 2022; 19(23).
65. Kaminski MR, Golledge J, Lasschuit JWJ, et al. Australian guideline on prevention of foot ulceration: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. *Journal of Foot and Ankle Research* 2022; 15(1): 53.
66. Fitridge R, Chuter V, Mills J, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer. *Journal of Vascular Surgery* 2023; 78(5): 1101–31.
67. Chuter V, Quigley F, Tosenovsky P, et al. Australian guideline on diagnosis and management of peripheral artery disease: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. *Journal of Foot and Ankle Research* 2022; 15(1): 51.
68. Bus SA, Sacco ICN, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). *Diabetes/Metabolism Research and Reviews* 2024; 40(3): e3651.
69. Baker IDI Heart and Diabetes Institute. National evidence-based guideline on prevention, identification and management of foot complications in diabetes (Part of the National Health & Medical Research Council Approved Guidelines on Management of Type 2 Diabetes). 2011. <https://www.baker.edu.au/impact/guidelines/guideline-foot-complication> (accessed 20 April 2023) 2023).
70. Parker CN, van Netten JJ, Parker TJ, et al. Differences between national and international guidelines for the management of diabetic foot disease. *Diabetes/Metabolism Research and Reviews* 2019; 35(2): e3101.
71. Podiatry Board of Australia. Registration data tables – March 2017. Australian Health Practitioner Regulation Agency <http://www.podiatryboard.gov.au/About/Statistics.aspx> 2017; Canberra.
72. Morbach S, Kersken J, Lobmann R, Nobels F, Doggen K, Van Acker K. The German and Belgian accreditation models for diabetic foot services. *Diabetes Metab Res Rev* 2016; 32 Suppl 1: 318–25.
73. Bergin SM, Gurr JM, Allard BP, et al. Australian Diabetes Foot Network: management of diabetes-related foot ulceration – a clinical update. *Medical Journal of Australia* 2012; 197(4): 226–9.
74. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. In: National Institute for Health and Care Excellence, editor.; 2019. <https://www.ncbi.nlm.nih.gov/books/NBK553608/> (accessed 11 June 2025).
75. Hamilton EJ, Scheepers J, Ryan H, et al. Australian guideline on wound classification of diabetes-related foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. *Journal of Foot and Ankle Research* 2021; 14(1): 60.
76. Chen P, Carville K, Swanson T, et al. Australian guideline on wound healing interventions to enhance healing of foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. *Journal of Foot and Ankle Research* 2022; 15(1): 40.
77. Commons RJ, Charles J, Cheney J, et al. Australian guideline on management of diabetes-related foot infection: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. *Journal of Foot and Ankle Research* 2022; 15(1): 47.
78. Fernando ME, Horsley M, Jones S, et al. Australian guideline on offloading treatment for foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease. *Journal of Foot and Ankle Research* 2022; 15(1): 31.
79. Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). *Diabetes Metabolic Research and Reviews* 2024; 40(3): e3646.
80. Bus SA, Armstrong DG, Crews RT, et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update). *Diabetes Metab Res Rev* 2024; 40(3): e3647.
81. Chen P, Vilorio NC, Dhataria K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). *Diabetes Metabolic Research and Reviews* 2024; 40(3): e3644.
82. Fitridge R, Chuter V, Mills J, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. *Diabetes Metab Res Rev* 2024; 40(3): e3686.
83. Monteiro-Soares M, Hamilton EJ, Russell DA, et al. Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update). *Diabetes Metab Res Rev* 2024; 40(3): e3648.

## REFERENCES

84. Senneville E, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). *Diabetes Metab Res Rev* 2024; 40(3): e3687.
85. Lazzarini PA, O'Rourke SR, Russell AW, Derhy PH, Kamp MC. Reduced incidence of foot-related hospitalisation and amputation amongst persons with diabetes in Queensland, Australia. *PLoS ONE* 2015; 10(6): e0130609.
86. Vo UG, Gilfillan M, Hamilton EJ, et al. Availability and service provision of multidisciplinary diabetes foot units in Australia: a cross-sectional survey. *Journal of Foot and Ankle Research* 2021; 14(1): 27.
87. National Association of Diabetes Centres and the Australian Diabetes Society. NADC Collaborative Interdisciplinary Diabetes High Risk Foot Services (HRFS) standards. Sydney; 2018. <https://nadc.net.au/hrfs-standards/> (accessed 11 June 2025).
88. Australian Commission on Safety and Quality in Health Care (ACSQHC) and National Health Performance Authority. Australian Atlas of Healthcare Variation. In: ACSQHC, editor. Sydney; 2016. <https://www.safetyandquality.gov.au/our-work/healthcare-variation/australian-atlas-healthcare-variation-series> (accessed 11 June 2025).
89. NHS. National Diabetes Foot Care Audit, Fourth Annual Report. 2019. <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-footcare-audit> (accessed 11 June 2025).
90. Zhang Y, Cramb S, McPhail SM, et al. Multiple factors predict longer and shorter time-to-ulcer-free in people with diabetes-related foot ulcers: Survival analyses of a large prospective cohort followed-up for 24-months. *Diabetes Research and Clinical Practice* 2022; 185: 109239.
91. Zhang Y, Cramb S, McPhail SM, et al. Factors associated with healing of diabetes-related foot ulcers: observations from a large prospective real-world cohort. *Diabetes Care* 2021; 44(7): e143-e5.
92. Smith-Strom H, Igland J, Ostbye T, et al. The effect of telemedicine follow-up care on diabetes-related foot ulcers: a cluster-randomized controlled noninferiority trial. *Diabetes Care* 2018; 41(1): 96-103.
93. Dardari D, Franc S, Charpentier G, et al. Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study. *Lancet Regional Health Europe* 2023; 32: 100686.
94. Rasmussen BS, Froekjaer J, Bjerregaard MR, et al. A randomized controlled trial comparing telemedical and standard outpatient monitoring of diabetic foot ulcers. *Diabetes Care* 2015; 38(9): 1723-9.
95. Santamaria N, Carville K, Ellis I, Prentice J. The Effectiveness of Digital Imaging and Remote Expert Wound Consultation on Healing Rates in Chronic Lower Leg Ulcers in the Kimberley Region of Western Australia. Primary Intention: The Australian Journal of Wound Management 2004; 12(2): 62.
96. Clinical Excellence Queensland. Access to ambulatory high risk foot project 2023. <https://clinicalexcellence.qld.gov.au/improvement-exchange/ambulatory-high-risk-foot-services> (accessed 26th October 2024).
97. Clinical Excellence Queensland. Community Foot Care Hubs project. 2024. <https://clinicalexcellence.qld.gov.au/improvement-exchange/community-foot-care-hubs> (accessed 26th October 2024).
98. Graham K, Siatas CM, Gunn KM, et al. The experiences of health workers using telehealth services for diabetes-related foot complications: a qualitative exploration. *Journal of Foot and Ankle Research* 2023; 16(1): 47.
99. Sherwood J. Colonisation-It's bad for your health: The context of Aboriginal health. *Contemporary Nurse* 2013; 46(1): 28-40.
100. Kairuz CA, Casanelia LM, Bennett-Brook K, Coombes J, Yadav UN. Impact of racism and discrimination on physical and mental health among Aboriginal and Torres Strait Islander peoples living in Australia: a systematic scoping review. *BMC Public Health* 2021; 21(1): 1302.
101. West M, Sadler S, Charles J, et al. Yarning about foot care: evaluation of a foot care service for Aboriginal and Torres Strait Islander Peoples. *Journal of Foot and Ankle Research* 2022; 15(1): 25.
102. Hayward MN, Pace R, Zaran H, et al. Closing the indigenous health gap in Canada: Results from the TransFORMATION of IndiGENous PrimARy HEALthcare delivery (FORGE AHEAD) program. *Diabetes Research and Clinical Practice* 2020; 162: 108066.
103. Chuter V, West M, Hawke F, Searle A. Where do we stand? The availability and efficacy of diabetes related foot health programs for Aboriginal and Torres Strait Islander Australians: a systematic review. *Journal of Foot and Ankle Research* 2019; 12(1): 1-12.
104. South Australian Health and Medical Research Institute. Aboriginal and Torres Strait Islander Diabetes-Related Foot Complications Program. 2024. <https://sahmri.org.au/research/themes/aboriginal-health/programs/health-systems-research/projects/aboriginal-and-torres-strait-islander-diabetes-related-foot-complications-program#:~:text=The%20Aboriginal%20and%20Torres%20Strait,the%20Kimberley%20region%20in%20Western> (accessed 19/10/24).
105. Australian Institute of Health & Welfare. Health system overview. 2024. <https://www.aihw.gov.au/reports/australias-health/health-system-overview> (accessed 26th October 2024).
106. Wounds Australia. The healing begins: Australian Government announces first ever wound care products support scheme. 2023. [https://woundsaustralia.org/ocd.aspx?action=check\\_bulletin&code=&mess\\_no=45\\_1684198881&bulletin\\_name=news\\_bulletin\\_1&category=](https://woundsaustralia.org/ocd.aspx?action=check_bulletin&code=&mess_no=45_1684198881&bulletin_name=news_bulletin_1&category=) (accessed 19/10/24).
107. Department of Health and Aged Care. \$3 million for better wound care. 2024. <https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/3-million-for-better-wound-care> (accessed 11 June 2025).
108. National Association of Diabetes Centres, Australian Diabetes Society. NADC Collaborative Interdisciplinary Diabetes High Risk Foot Services (iHRFS) Standards Review; Version 2.0. Sydney: National Association of Diabetes Centres; 2021. <https://nadc.net.au/hrfs-standards/> (accessed 11 June 2025).
109. National Association of Diabetes Centres. Interdisciplinary HRHS Accreditation. 2024. <https://nadc.net.au/hrfs-accreditation/> (accessed 26th October 2024).
110. Australian Commission on Safety and Quality in Health Care. The NSQHS Standards. 2021. <https://www.safetyandquality.gov.au/standards/nsqhs-standards> (accessed 26th October 2024).

## REFERENCES

111. Australian Government Department of Health and Aged Care. A National strategy for clinical quality registries and virtual registries 2020–2030. Canberra, 2023. <https://www.health.gov.au/resources/publications/a-national-strategy-for-clinical-quality-registries-and-virtual-registries-2020-2030?language=en> (accessed 11 June 2025).
112. Gregg EW, Buckley J, Ali MK, et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. *Lancet* 2023; 401(10384): 1302–12.
113. Lazzarini PA, Raspovic A, Prentice J, et al. 2021 Australian evidence-based guidelines for diabetes-related foot disease; Version 1.0. Brisbane: Diabetes Feet Australia, Australian Diabetes Society; 2021. <https://www.diabetesfeetaustralia.org/new-guidelines/> (accessed 11 June 2025).
114. Australian Government Department of Health. Australian National Diabetes Strategy 2021–2030. Canberra: Department of Health; 2021. <https://www.health.gov.au/resources/publications/australian-national-diabetes-strategy-2021-2030?language=en> (accessed 11 June 2025).
115. Joint Council on Closing the Gap. National agreement on closing the gap. 2020. <https://www.closingthegap.gov.au/joint-council-closing-gap> (accessed 11 June 2025).
116. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019; 95: 103208.
117. National Association of Diabetes Centres. Australian Diabetes HRFS Database. 2023. <https://nadc.net.au/hrfs-data-collection/> (accessed 1 December 2023).
118. Australian Commission on Safety and Quality in Health Care. ACSQHC-ARCR-321. 2024. <https://www.safetyandquality.gov.au/acsqhc-arcr-321>.
119. Australian Commission on Safety and Quality in Health Care. About PROMs. 2022. <https://www.safetyandquality.gov.au/our-work/indicators-measurement-and-reporting/patient-reported-outcomes/about-proms> (accessed 21 December 2022).
120. Koff E, Lyons N. Implementing value-based health care at scale: the NSW experience. *Medical Journal of Australia* 2020; 212(3): 104–6 e1.
121. Romero-Collado A, Hernandez-Martinez-Esparza E, Zabaleta-Del-Olmo E, Urpi-Fernandez AM, Santemas-Masana R. Patient-reported outcome measures of quality of life in people affected by diabetic foot: a psychometric systematic review. *Value Health* 2022; 25(9): 1602–18.
122. Australian Commission on Safety and Quality in Health Care, Australian Institute of Health and Welfare. The Fourth Australian Atlas of Healthcare Variation. Sydney: ACSQHC; 2021. <https://www.safetyandquality.gov.au/our-work/healthcare-variation/australian-atlas-healthcare-variation-series> (accessed 11 June 2025).
123. Donovan P, Eccles-Smith J, Hinton N, et al. The Queensland Inpatient Diabetes Survey (QuIDS) 2019: the bedside audit of practice. *Medical Journal of Australia* 2021; 215(3): 119–24.
124. Lazzarini PA, Ng V, Kinnear EM, et al. The Queensland high risk foot form (QHRFF) – is it a reliable and valid clinical research tool for foot disease? *Journal of Foot and Ankle Research* 2014; 7(1): 7.
125. Menz HB, Williams CM, Lazzarini PA, Gordon J, Harrison C. Foot, ankle, and leg problems in Australian primary care: consultation patterns, management practices, and costs. *Fam Pract* 2024; 41(14): 426–33.
126. Australian Commission on Safety and Quality in Health Care. Australian Framework for National Clinical Quality Registries 2024. Second edition ed. Sydney: ACSQHC; 2024. <https://www.safetyandquality.gov.au/publications-and-resources/resource-library/australian-framework-national-clinical-quality-registries-2024> (accessed 11 June 2025).
127. Jeffcoate W, Game F, Morbach S, Narres M, Van Acker K, Icks A. Assessing data on the incidence of lower limb amputation in diabetes. *Diabetologia* 2021; 64(6): 1442–6.
128. Jeffcoate W, Holman N, Rayman G, Valabhji J, Young B. New national diabetes footcare audit of England and Wales. *Diabetic Medicine* 2014; 31(9): 1022–3.
129. NHS Digital. NDFA Interval Review: July 2014–March 2021. 2022. <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-footcare-audit/2014-2021#top> (accessed 21 December 2022).
130. Yelland AC, Meace C, Knighton P, et al. Impact of case-mix adjustment on observed variation in the healing of diabetic foot ulcers at 12 weeks using data from the National Diabetes Foot Care Audit of England and Wales: A cohort study. *Diabetic Medicine* 2023; 40(1): e14959.
131. National Health and Medical Research Council. National Evidence-Based Guideline on Prevention, Identification and Management of Foot Complications in Diabetes (Part of the Guidelines on Management of Type 2 Diabetes). Melbourne: Australian Government; 2011. <https://www.baker.edu.au/-/media/documents/impact/diabetes-foot-guidelines/baker-institute-foot-complications-full-guideline.pdf?la=en> (accessed 11 June 2025).
132. National Health and Medical Research Council. Guidelines for Guidelines: Adopt, adapt or start from scratch. Version 5.2. 2018. <https://www.nhmrc.gov.au/guidelinesforguidelines/plan/adopt-adapt-or-start-scratch> (accessed 3 June 2024).
133. Bus SA, Armstrong DG, Gooday C, et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020; 36 Suppl 1: e3274.
134. Bus SA, Lavery LA, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020; 36 Suppl 1: e3269.
135. Bus SA, Van Netten JJ, Hinchliffe RJ, et al. Standards for the development and methodology of the 2019 International Working Group on the Diabetic Foot guidelines. *Diabetes Metab Res Rev* 2020; 36 Suppl 1: e3267.
136. Hinchliffe RJ, Forsythe RO, Apelqvist J, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020; 36 Suppl 1: e3276.
137. Lipsky BA, Senneville E, Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020; 36 Suppl 1: e3280.
138. Monteiro-Soares M, Russell D, Boyko EJ, et al. Guidelines on the classification of diabetic foot ulcers (IWGDF 2019). *Diabetes Metab Res Rev* 2020; 36 Suppl 1: e3273.

## REFERENCES

139. Rayman G, Vas P, Dhatariya K, et al. Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev* 2020; 36 Suppl 1: e3283.
140. Diabetes Feet Australia. Interactive DFD Guidelines for Health Professionals. 2021. <https://diabetesfeetaustralia.stonly.com/kb/en> (accessed 3 June 2024).
141. Bus SA, Monteiro-Soares M, Game F, et al. Standards for the development and methodology of the 2023 IWGDF guidelines. *Diabetes Metab Res Rev* 2024; 40(3): e3656.
142. van Netten JJ, Apelqvist J, Bus SA, et al. The International Working Group on the Diabetic Foot: stories and numbers behind three decades of evidence-based guidelines for the management of diabetes-related foot disease. *Diabetes Ther* 2024; 15(1): 19–31.
143. National Health and Medical Research Council. Procedures and requirements for meeting the NHMRC standards for clinical practice guidelines. Version 1.2. Melbourne: NHMRC; 2020. <https://www.nhmrc.gov.au/sites/default/files/documents/reports/clinical%20guidelines/Procedures-and-requirements-for-meeting-the-2011-NHMRC-standard-for-clinical-practice-guidelines%2801%29.pdf> (accessed 11 June 2025).
144. White H, Tendal B, Elliott J, Turner T, Andrikopoulos S, Zoungas S. Breathing life into Australian diabetes clinical guidelines. *Medical Journal of Australia* 2020; 212(6): 250–1 e1.
145. Living Evidence for Diabetes Consortium. Australian Evidence-Based Clinical Guidelines for Diabetes. Melbourne: Living Evidence for Diabetes Consortium; 2020. <https://www.diabetessociety.com.au/living-evidence-guidelines-in-diabetes/> (accessed 11 June 2025).
146. Diabetes Australia. 2024–25 Pre-budget submission: Diabetes Research, 2024. <https://www.diabetesaustralia.com.au/wp-content/uploads/2024-25-Pre-budget-submission-Final-Diabetes-in-Australia.pdf> (accessed 11 June 2025).
147. Armstrong DG, Kanda VA, Lavery LA, Marston W, Mills JL, Sr., Boulton AJ. Mind the gap: disparity between research funding and costs of care for diabetic foot ulcers. *Diabetes Care* 2013; 36(7): 1815–7.
148. Gilbert SE, Buchbinder R, Harris IA, Maher CG. A comparison of the distribution of Medical Research Future Fund grants with disease burden in Australia. *Medical Journal of Australia* 2021; 214(3): 111–3.e1.
149. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392(10159): 1859–922.
150. Kumlien C, Acosta S, Björklund S, et al. Research priorities to prevent and treat diabetic foot ulcers—A digital James Lind Alliance Priority Setting Partnership. *Diabetic Medicine* 2022; 39(11): e14947.
151. Australian Clinical Trials Alliance. Australian Clinical Trials Alliance. 2024. <https://clinicaltrialsalliance.org.au/> (accessed 8th October 2024).
152. Bainbridge R, Tsey K, McCalman J, et al. No one’s discussing the elephant in the room: contemplating questions of research impact and benefit in Aboriginal and Torres Strait Islander Australian health research. *BMC Public Health* 2015; 15(1): 696.
153. Australian Institute of Aboriginal and Torres Strait Islander Studies (AIATSIS). AIATSIS Code of Ethics for Aboriginal and Torres Strait Islander Research. Canberra, 2020. <https://aiatsis.gov.au/research/ethical-research/code-ethics> (accessed 11 June 2025).
154. Gerrard JM, Godwin S, Chuter V, Munteanu SE, West M, Hawke F. Release of the National Scheme’s Aboriginal and Torres Strait Islander Health and Cultural Safety Strategy 2020–2025; the impacts for podiatry in Australia: a commentary. *Journal of Foot and Ankle Research* 2021; 14(1): 38.
155. Smith L. Decolonizing methodologies: Research and indigenous peoples: Zed Books Ltd; 2021.
156. Jeffcoate WJ, Bus SA, Game FL, Hinchliffe RJ, Price PE, Schaper NC. Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality. *Lancet Diabetes Endocrinol* 2016; 4(9): 781–8.
157. Staniszewska A, Game F, Nixon J, et al. Development of a core outcome set for studies assessing interventions for diabetes-related foot ulceration. *Diabetes Care* 2024; 47(11): 1958–68.
158. Australian Bureau of Statistics (ABS). Population. 2024. <https://www.abs.gov.au/statistics/people/population> (accessed 13 March 2024).
159. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. *J Vasc Surg* 2019; 69(6s): 3S–125S.e40.
160. Baba M, Davis WA, Norman PE, Davis TM. Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes Study. *Cardiovasc Diabetol* 2015; 14: 152.
161. Kurowski JR, Nedkoff L, Schoen DE, Knuiman M, Norman PE, Briffa TG. Temporal trends in initial and recurrent lower extremity amputations in people with and without diabetes in Western Australia from 2000 to 2010. *Diabetes Research and Clinical Practice* 2015; 108(2): 280–7.
162. Young MJ, McCardle JE, Randall LE, Barclay JL. Improved survival of diabetic foot ulcer patients 1995–2008: possible impact of aggressive cardiovascular risk management. *Diabetes Care* 2008; 31(11): 2143–7.
163. National Institute of Clinical Excellence (NICE). NICE Guideline: Diabetic foot problems: prevention and management (NG19). London, United Kingdom: National Institute for Health and Care Excellence (NICE), 2023 <https://www.ncbi.nlm.nih.gov/books/NBK553608/> (accessed 11 June 2025).